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1. Introduction  
Gastric carcinoma (GC) remains one of the most malignant tumors either in morbidity or 
mortality rates around the world (IARC, 2002). Development of GC is influenced by 
multiple factors including genetic, biological, social, and psychological ones, etc.., however, 
the function mechanisms of which are too sophisticated and still under explorations 
(Matysiak-Budnik & Mégraud, 2006). Similar to other malignant tumors, GC leads to death 
mainly due to system or organ failure because of cancer advancement and metastasis. 
Chemotherapy-based regimens combined with radiological and immunomodulating 
therapies are fundamental but unsatisfactory because most GC patients are in advanced 
stage when diagnosed, although radical operation throws those at early stage a light of 
prolonged survival and even clinical cure (Quiros & Bui, 2009). As for prophylaxis, many 
reports have mentioned the protective role of eradication of Helicobacter pylori, which has 
been identified as a definite carcinogen for GC, but few evidences proved a successful H. 
pylori vaccine showing effects on GC prevention, just as Hepatitis B virus vaccine on 
prevention of primary hepatocellular carcinoma (IARC, 1994; Murakami et al., 2005; Cai et 
al., 2005; Di Bisceglie 2009).  
H. pylori, a stomach colonizing spiral gram-negative bacterium, interacts with the host in a 
multiplicity of ways during its adhesion, colonization, invasion, and induction of 
inflammatory and immune responses (Peek 2005). The great majority of researchers link H. 
pylori infection with development or even recurrence of GC according to some clinical trials, 
meta-analyses, and in vitro experiments (Wong et al., 2004; Fukase et al., 2008). However, a 
few recent studies have disclosed the other side of the coin, in which positive H. pylori status 
appears to be associated with better outlook in GC patients (Meimarakis et al., 2006; Marrelli 
et al., 2009). Therefore, H. pylori probably factually play a bi-directional role in GC just like a 
double-edged sword. To learn about both edges of H. pylori infection will provides us with 
new sights in vaccine design, prevention, and even therapy of GC. 
Herein, we try to re-elucidate the relationship between H. pylori and GC from novel angles, 
in which GC consists of H. pylori-related (Hp-GC) and non-H. pylori-related (nHp-GC) ones, 
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and in which roles of the infection are divided into two parts including harmful and 
beneficial ones.  
2. H. pylori virulence factors 
H. pylori infection usually initiates from bacterial invasion, colonization, and expression and 
translocation of virulence factors, and persists through induction and maintenance of 
complex responses at certain levels in the host (Peek 2005). Herein, virulence factors 
extensively mean pathogenic components and contain those contributing to bacterial 
survival within the host, which are ever called as maintenance factors sometimes. According 
to the complete genome published and continuously updated since 1997, H. pylori (26695 
strain) is of about 1.67 Mb in length with 1576 protein-coding genes, many of which encode 
virulent products associated with H. pylori pathogenesis (Tomb et al., 1997).  
The cytotoxin-associated gene (cag) pathogenicity island (PAI), one of most well known 
virulence components, is of about 35 Kb with 26 open reading frames and is present in 
about 60% H. pylori strains in Europe and United States (Tomb et al., 1997; Peek 2005). 
Among all Cag PAI products, the CagA (Cag26) has been identified with relatively clear 
functions in development of GC (Huang et al., 2003). The involved carcinogenic mechanisms 
of CagA mainly include activation of certain signalling pathways such as Ras, SHP2, ERK, 
MAPK and JAK/STAT3, activation of C-terminal Src kinase and inhibition of Src activity, 
enhancement of epithelial gene transcription, disruption of cellular polarity, and 
morphological changes and final transformation of gastric epithelial cells (GECs) (Mimuro 
et al., 2002; Higashi et al., 2002; Selbach et al., 2002; Bagnoli et al., 2005; Lee et al., 2010).  
Vacuolating toxin (vacA) of about 3.9 Kb is an independent key virulence determinant for H. 
pylori pathogenesis (Tomb et al., 1997). Around 60% of H. pylori strains produce detectable 
amounts of VacA in vitro, although this gene is present in all strains (Konturek et al., 2009). 
Cytotoxic activity of VacA varys considerably in different strains due to various gene 
subtypes based on sequence diversities in the N-terminal (allele types s1a, s1b, s1c, or s2) 
and middle regions (allele types m1 or m2) (Atherton et al., 1995; Peek 2005). It has been 
demonstrated that infection with vacA s1 and m1 strains are associated with an increased 
risk of GC (Gerhard et al., 1999). VacA plays a role in carcinogenesis probably through 
inducing vacuolation and cellular detachment, permeabilizing epithelial cells, promoting 
apoptosis, and suppressing T-cell proliferation and activation (Peek 2005).  
Outer membrane proteins (OMP) represent a large family of adhesins and participate in H. 
pylori infection mainly by mediating bacterial adherence and colonization in gastric mucosa 
(Odenbreit 2005). As one of OMP members, blood-group antigen-binding adhesin (BabA) 
can bind the blood-group antigen Lewis b on host epithelial cell membranes, and those 
strains possessing the encoding gene babA2 are associated with high risk of GC (Oliveira et 
al., 2003; Konturek et al., 2009). Lipopolysaccharide (LPS), another cell wall component, can 
disrupt stomach mucosa and involve in the organism survival and persistence of H. pylori 
infection (Grebowska et al., 2008). Moreover, the LPS O-antigen mimics human Lewisx and 
Lewisy blood-group antigens, which also mediate bacterial adhesion and colonization and 
alternatively cause immune cross-reactivity (Moran 1996; Appelmelk et al., 2001).  
There are still many other important virulence factors related with H. pylori infection and 
even carcinogenesis. Urease, an approximately 560-kDa hexameric enzyme consisting of 30-
kDa UreA and 64-kDa UreB subunits, is produced abundantly by all H. pylori isolates 
(Turbett et al., 1992). Urease is independently essential for colonization and persistent 
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survival of the germ because it crucially contributes to local pH homeostasis within the 
stomach lumen (Stingl et al., 2002; Mollenhauer-Rektorschek et al., 2002). The induced by 
contact with epithelium factor Antigen (IceA), with two major allelic sequence variants of 
IceA1 and IceA2, is an independent strain-specific H. pylori locus significantly associated 
with distal GC (Kidd et al., 2001). IceA1 leads to relatively severer gastric inflammation and 
tissue damage following production induced by bacterial contact with GECs, which exists in 
72% of the H. pylori isolates in a Chinese population (Sheu et al., 2002). Flagella are bacterial 
motile structures with two types of filaments, that are encoded by flaA and flaB genes and 
functionaly regulated by flgE and flbA genes (Dunn et al., 1997). Normal expression and 
interaction of these virulence factors are required for bacterial motility or colonization 
during H. pylori infection. 
Notably, H. pylori plays pathogenic or carcinogenic roles as an integrity, although its 
multiple virulence components have their own special contributions at various infection 
stages. The co-interactions among the virulence factors are likewise important for 
pathogenesis but may be so complex or always ignored and need further explorations. In 
addition, cross-interactions between H. pylori and the host are very vital for infection or 
carcinogenesis, which mainly contain inflammatory and immune responses, and genetic or 
phenotypic alterations (McNamara & El-Omar, 2008). 
3. Inflammatory responses 
H. pylori infection is firstly characterized by acute or chronic activation of inflammatory cells 
and release of multiple cytokines including pro-inflammatory and inflammatory ones (Peek 
2005). The spectrum and relative levels of cytokines, to a certain extent, reflect the intensity 
of the host response to infection, which may result in different outcomes including gastric 
mucosal inflammation, injury, ulcer, and even cancer. 
Cytokines such as tumor necrosis factor ǂ (TNF-ǂ), interleukin-1ǃ (IL-1ǃ) / IL-1 receptor 
antagonist (IL-1RN), IL-6, IL-8 and IL-10 are always significantly up-regulated in stomach 
mucosa, gastric fluids and the sera of H. pylori-infected patients and play vital functions in 
gastritis, metaplasia, dysplasia and carcinogenesis (McNamara & El-Omar, 2008). TNF-ǂ 
and IL-1 are the most relevant factors consistently confirmed in animal models and various 
populations. TNF-ǂ can markedly potentiate apoptosis, activate signalling pathways, 
influence mucosal inflammation and stimulate gastric acid secretion (Ierardi et al., 2003). 
Moreover, H. pylori causes sensitization of GECs for TNF-related apoptosis-inducing ligand 
(TRAIL)-mediated apoptosis, besides direct induction of apoptosis and inhibition of DNA 
synthesis (Tsai & Hsu, 2010). The H. pylori infection strengthens IL-1 functions in the 
carcinogenic process through complex pathways. IL-1ǃ and IL-1RN as key pro-
inflammatory genotypes of IL-1, which is a powerful gastric acid suppressor, can increase 
the risk of atrophic gastritis (AG) and both intestinal and diffuse types of non-cardia GC 
(Starzyńska et al., 2006; Rad et al., 2004). IL-1ǃ with significantly higher level in neoplasm 
than in normal mucosa, involves in the carcinogenesis by stimulating hyper-proliferation in 
GECs via tyrosine kinase signalling (Beales 2002). H. pylori-induced gastritis is possibly 
driven in an IL-6-dependent fashion (Jackson et al., 2006). IL-6 participates in activation of 
the STAT3 signalling pathway by the translocated CagA in host cells, which may play a role 
in gastric carcinogenesis (Bronte-Tinkew et al., 2009). IL-6 level in the serum is related with 
GC status and its level in the tumor correlates significantly with lymphatic invasion and the 
depth of invasion (Kai et al., 2005). As for IL-8, its level in cancer tissues is more than double 
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fold in advanced GC than that in early GC irrespective of H. pylori status (Yamaoka et al., 
2001). IL-8 modulates gastric acid secretion, promotes the proliferation, enhances the FasL-
induced apoptosis, and mutually and dependently activates NF-κB (Konturek et al., 2002; 
Varro et al., 2004; Guo et al., 2006). Moreover, IL-8 as a potent leukocyte chemoattractant, 
contributes to mucosal tissue injury and induces the upregulation and phosphorylation of 
EGFR and subsequent signalling events, which plays an fundamental role in carcinogenic 
mechanisms (Kassai et al., 1999; Beswick & Reyes, 2008). IL-10 inhibits the FasL-induced 
apoptosis in GECs though without significant effect on the transcription of Fas (Guo et al., 
2006). IL-11 activates the STAT3 like IL-6 and concomitantly increases proliferation of GECs 
(Jackson et al., 2007). 
Some other molecules including cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), nitric 
oxide (NO), inducible NO synthase (iNOS), monocyte chemoattractant protein 1 (MCP1), 
and hepatocyte growth factor (HGF) and c-MET also relate to GC-associated inflammatory 
responses (Zhuang X et al., 2001; Futagami et al., 2008; Snider & Cardelli, 2009; Cho et al., 
2010). COX-2 as a key mediator in inflammation and cancer formation, together with PGE2, 
one of its major products, are remarkably up-regulated in H. pylori-related gastritis, GC, and 
precancerous lesions including atrophy, intestinal metaplasia (IM) and dysplasia of the 
stomach (Dong et al., 2009; Walduck et al., 2009; Zhang et al., 2009). COX-2 can be induced 
by gastrin, growth factors, inflammatory cytokines and reactive oxygen species in GECs 
(Seo et al., 2007). The overexpression of COX-2 may continue to exist in metaplastic or 
dysplastic mucosa even after successful H. pylori eradication, which increases the risk for 
carcinogenesis and indicates that COX-2 has a crucial role in not only Hp-GC but also nHp-
GC (Tsuji et al., 2006). COX-2 overexpression is even thought as a biomarker of intestinal 
type and earlier stage of GC and an independent prognostic factor for worse survival (Park 
et al., 2009). COX-2 induces carcinogenesis mainly by inhibiting apoptosis, increasing 
proliferation and enhancing angiogenesis through multiple pathways including Wnt 
signalling, p38MAPK / ATF-2 pathway, TLR2 / TLR9 and c-Src-dependent NF-κB 
activation, MMP-9 and VEGF activation, proteinase-activated receptor-2 signalling, PPARǄ 
inhibition, and so on (Leung et al., 2003; Chang  et al., 2004 & 2005; Huang et al., 2006; Li et 
al., 2009; Zhang et al., 2009; ). PGE2, a downstream mediator with central roles in the 
mentioned COX-2 pathways, plays important functions in both inflammation and 
carcinogenesis. PGE2 participates in IL-8 production in GECs, facilitates H. pylori 
colonization and persistent infection, and suppresses the immune functions of CD4 (+) T-
helper 1 cells by silencing IL-2 gene transcription, which may help accelerate the tumor 
formation (Takehara et al., 2006; Toller et al., 2010).  
During chronic H. pylori infection, there are still excessive amounts of reactive oxygen and 
nitrogen species containing NO and iNOS, which play crucial roles in the stepwise process 
of GC (Son et al., 2001; Tiwari et al., 2010). NO as an important endogenous carcinogenic 
factor, correlates with gastric hypoacidity, inhibits p53 expression, increases genetic and 
epigenetic changes by mediating mutation or DNA methylation, and perturbs the balance 
between apoptosis and proliferation in GECs (McGee & Mobley, 2000; Lamarque et al., 2003; 
Shiotani et al., 2004; Chen et al., 2006; Katayama et al., 2009; ). Being one of independent 
prognostic factors, the iNOS overexpression is induced by H. pylori infection with 
involvements of TNF-ǂ, Ras, AP-1, c-Fos and c-Jun, and related to apoptosis, angiogenesis, 
tumor progression, and poor survival in GC especially of the intestinal type (Tatemichi et 
al., 1998; Rieder et al., 2003; Chen et al., 2006; Cho et al., 2010). MCP-1 is significantly higher 
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at mRNA level in poorly differentiated GC, which has effect on COX-2 expression and 
subsequent PGE2 and VEGF production (Futagami et al., 2008). HGF is more frequently 
detected in GC tissue than in normal mucosa and shows a concentration-dependent increase 
under the stimulation of gastrin (Konturek et al., 2001 & 2003). Being the receptor of HGF, c-
Met is activated by H. pylori, involved in malignant transformation of gastric mucosa and 
invasive growth of tumor cells, and strongly implicated in late-stage cancer progression and 
worse prognosis (Zhuang X et al., 2001; Churin et al., 2003; Snider & Cardelli, 2009). In 
addition, H. pylori-mediated GEC invasion depends on c-Met activation, besides on 
increased activities of MMP-2 and MMP-9 (Oliveira et al., 2006). The c-Met interacts with 
CagA and suppresses the phosphatidylinositol 3-kinase/Akt pathway, which then leads to 
ǃ-catenin activation and NF-κB signalling (Suzuki et al., 2009). 
4. Immune responses 
Another critical aspect of interactions between H. pylori and the host are immune responses, 
which consist of special and unspecialized ones. In fact, immune and inflammatory 
responses overlap each other especially in roles of many cytokines mentioned above during 
the infection and carcinogenesis. Herein we mainly focus on important alterations in 
antibody responses, status of immune cells, balance of cytokines, autoimmune reactions and 
immune tolerance. 
4.1 Antibody responses 
A significantly higher seroprevalence has been found in H. pylori-infected patients with 
gastritis, duodenal ulcer, or GC (Przyklenk et al., 1990). Some scientists have concluded that 
higher H. pylori seroprevalence is present in GC patients at early stages of tumor 
development compared those at advanced stages, whereas others have not (Lin et al., 1993; 
Klaamas et al., 1996; Komoto et al., 1998). Seropositivity of anti-H. pylori IgG is highly 
prevalent with 76% at 0-4 years and 99% by > or = 18 years of age in a rural population of 
Africa, where the immunological response is Th2-dominant, which may partly explain the 
lower risk of Hp-GC (Mbulaiteye et al., 2006). The immune serum-treated H. pylori cannot be 
eliminated in vitro by primary human macrophages, although serum enhances the bacteria 
uptake (Keep et al., 2010). Antibodies are not only dispensable for protection, but they 
impair both the elimination of bacteria and the development of gastritis. This effect appears 
to be IgA-dependent and is not a function of specific IgM or IgG antibodies (Akhiani 2005).  
The major antibodies responsive to H. pylori include IgA and IgG. GC patients elicit different 
anti-H. pylori IgG and IgA responses than the patients with atrophic and superficial gastritis 
(Manojlovic et al., 2008). IgA>IgG ratio and lower IgG is significantly more frequent in 
patients with GC and gastric lymphoma than those with gastritis and duodenal ulcer. 
Correspondingly, higher IgG and IgA levels are often observed in patients with duodenal 
ulcer or non-atrophic gastritis (Manojlovic et al., 2004 & 2008). As for subclass of IgG 
response, the IgG1 is lower in GC and AG patients than in gastritis ones; IgG2 is lower for 
patients with GC localized in the corpus. The IgG1 response in GC patients is correlated 
with H. pylori CagA status (Vorobjova et al., 2006). CagA-positive H. pylori strains also seem 
to markedly frequently induce an IgA response than CagA-negative strains. The presence of 
serum IgA antibodies likely indicates more severe late outcome of H. pylori infection 
(Rautelin et al., 2000). Anti-CagA antibodies are always higher in GC and AG compared 
with non-atrophic gastritis. As reported, Hp-GC patients are of 2-3 folds higher in CagA 
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seropositivity than age-matched H. pylori-positive non-GC controls. In addition, anti-CagA 
antibodies are significantly more prevalent among individuals with elevated titres of H. 
pylori-related IgA than in those only with IgG, with the exception of a small subgroup who 
later develop GC (Rautelin et al., 2000).  
Heat shock protein (HSP) 60 may be associated with H. pylori-related gastritis and gastric 
carcinogenesis. The positivity rate for anti-HSP60 antibody is markedly higher not only in 
H. pylori-positive patients than in H. pylori-negative ones, but also in GC patients, especially 
of the diffuse type, than in H. pylori-positive non-GC patients (Tanaka et al., 2009). The 
isocitrate dehydrogenase (ICD) of H. pylori, as an antigen interacting with the host immune 
system subsequent to a possible autolytic release, significantly elicits humoral immune 
response and reveals high serum antibody titers in patients with gastritis and ulcer (Hussain 
et al., 2008). In addition, the H. pylori-induced inflammation  leads to aberrant glycosylation 
and demasking of core peptide epitope of mucin 1 (MUC1), which could enhance the host 
immune responses (Klaamas et al., 2007). IgG immune response to tumor-associated MUC1 
is up-regulated among H. pylori-infected individuals and related with a higher degree of 
inflammation in gastric mucosa. The level of anti-MUC1 IgG is positively correlated with 
that of anti-H. pylori IgG in both blood donors and patients with benign diseases, whereas 
the anti-MUC1 IgM level is not (Klaamas et al., 2007). Moreover, the anti-MUC1 IgG level is 
notablely higher in GC patients than in blood donors, irrespective of H. pylori status or 
cancer stage. In some individuals, the H. pylori infection may stimulate specific response to 
tumor-associated MUC1 peptide thus modulating tumor immunity (Klaamas et al., 2007).  
4.2 Status of immune cells 
The infiltration of T, B and macrophage cells always increases at the gastric site of infection 
with H. pylori. The status of T cells and macrophage are closely associated with local and 
system protective immune responses including native and acquired ones, whereas B cells 
mainly play more roles in antibody responses and deregulated and exhaustive H. pylori-
induced T cell-dependent B-cell activation even supports the onset of stomach B-cell 
lymphoma (D'Elios et al., 2005).  
The tumor-infiltrating lymphocytes (TIL) from primary tumors have been isolated and 
analyzed to characterize the anti-tumor immune responses in GC patients (van den Engel et 
al., 2006). The CD3 (+) T cell population contains 50% CD4 (+) and 39% CD8 (+) cells. The 
number of CD19 (+) B cells significantly increases but that of CD3 (+) T cells significantly 
decreases in intestinal compared to diffuse type of GC. Most of T cell cultures derived from 
isolated TILs in Hp-GC patients secrete both IFN-Ǆ and IL-5 when stimulated with 
autologous tumor cells (van den Engel et al., 2006).  
There is a significant tendency of Th1/Th2 polarization in patients with H. pylori infection, 
especially of those with CagA positive strains (Wang et al., 2007). Protection against H. pylori 
infection including inhibition of bacterial colonization, is mainly mediated by CD4 (+) Th1 
cell -mediated immunity (Inoue et al., 2009). Th1-mediated cellular immunity is associated 
with earlier stages of GC, while Th2-mediated humoral immunity dominates the advanced 
stages and is negatively associated with an abundance of regulatory T-cells (Treg) (Wang et 
al., 2007).  
Treg cells of positive CD4, CD25 and Foxp3, suppress the host immune response to H. pylori 
infection and have been identified as the major regulatory factor of adaptive immune 
responses (Kandulski et al., 2010). Vaccine-induced protection against H. pylori correlates 
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with an augmented local recall response in the gastric mucosa, reduced amount of Treg, and 
increased proportions of neutrophils and CD4 (+) T cells (Becher et al., 2010). The CD4 (+) T 
cells isolated from stomachs of vaccinated mice can proliferate in vitro in response to H. 
pylori antigen, and secrete Th1 cytokines, particularly IFN-Ǆ. The efficiency of these vaccines 
relates to the alteration of gastric immune responses, from a homogeneous Th1 response to a 
mixed Th1 and Th2 response (Ernst et al., 2001). The functions of Treg cells are either 
mediated by direct cell-cell contact or by secretions of the immune-modulating TGF-ǃ1 and 
IL-10 cytokines (Kandulski et al., 2010). Treg is involved in bacterial persistence, increased in 
H. pylori-associated gastritis, and even positively related with the grade of chronic 
inflammation and the number of lymphoid follicles (Jang 2010). Treg is also markedly 
elevated in patients with GC compared to those with chronic gastritis and gastric dysplasia. 
Additionally, H. pylori may direct immunosuppression of T cells and regulate the host 
immune responses through activation of Treg and dendritic cells (Blanchard et al., 2004). 
Macrophages are essential components of innate immunity, and their apoptosis will impair 
the host mucosal defense to microbes (Asim et al., 2010). H. pylori infection leads to a rapid 
infiltration of macrophages into the mouse stomach. H. pylori also activates TLR-2 and TLR-
4 in macrophages, and subsequently induces the secretion of distinct cytokines including IL-
2, IL-6 and IFN-ǂ (Obonyo et al., 2007). However, the bacteria remain viable when 
internalized by GECs or even macrophages, which indicates the killing defects in the host 
due to inhibition of the phagosome maturation (Keep et al., 2010). In addition, H. pylori 
induces the formation of a specific phospho-c-Fos c-Jun activator protein-1 (AP-1) complex 
in gastric macrophages by an ERK-dependent way, that causes apoptosis and contributes to 
immune escape of the germ (Asim et al., 2010). 
Several H. pylori proteins can impair macrophage and T cell functions in vitro through 
unclear mechanisms (Zabaleta et al., 2004). VacA, known as a toxic protein with vacuolating 
activity, can induce apoptosis in GECs, affect antigen presentation by B lymphocytes, inhibit 
T cell activation and proliferation, and modulate the T cell-mediated cytokine responses, 
which mainly target the adapted immune system (Gebert et al., 2004). CagA is also capable 
of preventing hydroxyurea-induced B-cell apoptosis by reducing p53 accumulation 
(Umehara et al., 2003). The arginase may impair T cell functions through inhibiting 
proliferation and the TCR zeta-chain (CD3zeta) expression, besides its role in urea 
production (Zabaleta et al., 2004).  
4.3 Network of cytokines 
H. pylori-stimulated host inflammatory and immune responses lead to release of a large 
amount of cytokines, which contribute to the loss of balance between cell proliferation and 
apoptosis prior to many gastric lesions including AG and GC. There is a shift from Th1 
(IFN-Ǆ, TNF-ǂ and IL-12) towards Th2 (IL-4, IL-10 and IL-6)-type immune response in 
patients with GC and dysplasia (Marotti et al., 2008). IL-13 is recently described as a central 
mediator of Th2-dominant immune response and may be implicated in different outcomes 
of H. pylori infection (Marotti et al., 2008). TGF-ǃ and IL-10 are two vital anti-inflammatory 
cytokines that regulate mucosal immunity in various infectious diseases (Wu et al., 2007). 
The local and systemic T-cell response in Hp-GC patients is mainly characterized by 
production of IL-10 (Lundin et al., 2007). When stimulated with H. pylori antigens, T cells 
from both peripheral blood and gastric mucosa produce significantly higher amounts of IL-
10 in Hp-GC patients than in H. pylori-infected asymptomatic subjects. In addition, the 
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frequency of activated CD8 (+) T cells is markedly reduced in stomach mucosa of GC 
patients compared to asymptomatic individuals (Lundin et al., 2007). Therefore, the 
increased production of the suppressive cytokine IL-10 in Hp-GC patients may lead to a 
diminished local cytotoxic anti-tumor T-cell response and even contributes to cancer 
progression.  
A predominant H. pylori-specific Th1 response associates with peptic ulcer, whereas 
combined secretion of both Th1 and Th2 cytokines are present in simple gastritis (D'Elios et 
al., 2005). In H. pylori-infected mice, the local Th1-type response might alter the systemic 
Th1/Th2-type cytokine balance under particular physiopathological conditions of active 
tissue and/or vascular formation, such as pregnancy (Rossi et al., 2004). H. pylori neutrophil-
activating protein is able to recruit leukocytes and stimulate neutrophils or monocytes to 
release IL-12, a key cytokine for the differentiation of naive Th cells into the Th1 phenotype 
(D'Elios et al., 2007). During H. pylori infection, activated macrophages produce IL-18, which 
stimulates the IFN-Ǆ secretion by NK and T cells (Kawabata et al., 2001). Nevertheless, Th1 
immune response in the stomach may destroy the proliferation / apoptosis balance and 
promote the severity of H. pylori-induced gastric lesions (Xia et al., 2001; Vivas et al., 2008). 
In the host, the innate immune response usually represents by TLRs and Nod-like receptors 
that recognize their specific ligands, activate transcription factors including NF-kB, AP-1 
and CREB-1, and induce inflammatory cytokines such as IL-8, IL-12, IL-6, IL-1ǃ, IL-18, TNF-
ǂ and IL-10 (Sánchez-Zauco et al., 2010). Amounts of the tumor suppressor p53 and the 
major innate immune hub protein TRAF-6 reduce in H. pylori-infected gastric cells, and 
coincide with a partially cagPAI-dependent decrease in the expression and activity of 
deubiqutinating enzyme USP7, which indicates that H. pylori may also influence some 
immunity-associated cytokines through interfering in the host ubiquitin pathways (Coombs 
et al., 2010).  
During H. pylori infection, significant overexpression of MHC II antigen-presenting genes, 
IL-7R ubiquitin-D, CXCR4, lactoferrin immune response-related genes, CXCL-2 and -13, 
CCL18 chemokine ligand, and VCAM-1 genes have been established (Galamb et al., 2008). 
In addition, IL-23p19 up-regulation is confirmed in gastric biopsies from both H. pylori 
infected-mice and patients with chronic gastritis (Vivas et al., 2008). CCR6 is markedly 
upregulated in CD3 (+) T cells infiltrating the gastric mucosa and has been reported to 
mediate lymphocyte homeostasis and immune responses in mucosal tissue (Wu et al., 2007; 
Tsai & Hsu, 2010). CCL20, the ligand to CCR6, selectively expresses in inflamed stomach 
tissues and is upregulated in response to H. pylori in GECs stimulated by IL-1ǃ and TNF-ǂ. 
Furthermore, recombinant CCL20 induces lymphocyte chemotaxis migration in fresh gastric 
T cells in vitro (Wu et al., 2007). The interaction between CCR6 and CCL20 plays a potential 
role in recruiting T cells to inflamed gastric epithelium during H. pylori infection (Tsai & 
Hsu, 2010). 
4.4 Autoimmune and immune tolerance 
H. pylori has evolved means to structurally alter its surface characteristics to evade innate 
and adaptive immune responses (Nilsson et al., 2006). H. pylori expresses mimicry of some 
ABO blood group antigens (Moran et al., 2010). Additionally, CagA, VacA and BabA can 
mimic and bind to specific receptors or surface molecules on GECs and platelets (Höcker & 
Hohenberġer 2003; Takahashi et al., 2004; Hennig et al., 2004; Baldari et al., 2005). It has been 
shown that anti-CagA, anti-VacA and anti-BabA antibodies targeting both H. pylori 
components and host mimic molecules can be detected in the majority of GC patients with 
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increased levels (Rudi et al., 1997; Vaucher et al., 2000; Sokic-Milutinovic et al., 2004). H. 
pylori LPS is of underacylation and underphosphorylation and has significantly lower 
endotoxic and immuno-activities, which may lead to the infection chronicity (Moran et al., 
2010). H. pylori produces LPS O-antigen units that can be posttranslationally fucosylated to 
generate Lewis antigens, which are also found on human GECs, and this molecular mimicry 
induces autoreactive antibodies (Nilsson et al., 2006). Circulating anti-Lewis antibody is 
detected in the sera of GC patients but not in H. pylori-negative control subjects (Hynes et al., 
2005). Absorption of the sera with outer membrane vesicles decreases anti-Lewis 
autoantibody level. The ability of these vesicles to absorb anti-Lewis autoantibody indicates 
that they partly play a role in putative autoimmune aspects of H. pylori pathogenesis (Hynes 
et al., 2005). 
As reported, C57BL/6 mice infected with CagA (+) H. pylori during the neonatal period tend 
to be protected from preneoplastic lesions, compared to those infected with the same strain 
at 5-6 weeks of age (Arnold et al., 2011). This protection results from the development of H. 
pylori-specific peripheral immunologic tolerance, which is mediated by long-lived inducible 
Treg and controls the local CD4 (+) T-cell responses that trigger premalignant 
transformation. Moreover, both the biased ratio of Treg to T-effector cells in the neonatal 
period and prolonged low-dose exposure to antigens contribute to the development of 
immune tolerance to H. pylori (Arnold et al., 2011). In addition, exposure of cells to most 
microbial pathogens can up-regulate HSPs, whereas H. pylori decreases expression of HSPs 
including HSP8, HSP70, HSP60, and heat shock factor 1 (HSF-1). The down-regulation of 
HSPs may be a mechanism of immune evasion that promotes chronic H. pylori infection 
(Axsen et al., 2009). NO / iNOS as one part of the host innate defense system, determines 
the killing efficiency of H. pylori by macrophages. H. pylori up-regulates arginase II (Arg2) 
expression, resulting in reduction of NO / iNOS production and decreased killing of the 
germ by macrophages, which implicates another potential mechanism of the immune 
evasion of H. pylori (Lewis et al., 2010). 
5. Genetic and phenotypic alterations 
Some polymorphisms of certain genes including IL-1, IL-4, IL-6, IL-8, IL-10, TNF, iNOS and 
COX-2, which likely differ in various host species, play important roles in the inflammation, 
immune responses, and gastric carcinogenesis, besides in susceptibility to H. pylori infection. 
The GC risk-associated alleles are more prevalent in certain subjects of special human races, 
geographic regions, and H. pylori infection status. Thus, genetic and phenotypic 
backgrounds of H. pylori may interact with mentioned host factors and influence the related 
biological or pathological processes. 
5.1 IL-1 
IL-1ǃ and IL-1RN polymorphisms relate to the development of GC and H. pylori infection 
markedly increases the risk, which supports the association of these polymorphisms with 
risk of Hp-GC (Al-Moundhri et al., 2006). Either infection with vacA s1 (+), vacA m1 (+) and 
cagA (+) strains or the host genotype of IL-1ǃ -511T homozygous for IL-1RN2/2 allele is 
associated with an increased GC risk (Figueiredo et al., 2002). Individuals with 
polymorphisms in IL-1 and TNF-ǂ genes have the highest risk of GC, when they are 
simultaneously infected by virulent H. pylori strains of cagA (+), vacA s1 (+), vacA m1 (+) 
and babA2 (+). As for IL-1 gene, the odds of developing GC are greatest in those with 
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combination of high-risk bacterial / host genotypes such as vacA s1 / IL-1ǃ -511T, vacA m1 
/ IL-1ǃ -511T, cagA (+) / IL-1ǃ -511T, vacA s1 / IL-1RN2/2, vacA m1 / IL-1RN2/2, and 
cagA (+) / IL-1RN2/2 (Figueiredo et al., 2002).  
IL-1ǃ -511T/-31C (+) and IL-1RN2 (+) polymorphisms are associated with severe degrees of 
inflammation, prevalence of IM and AG, and increased expression of IL-1ǃ, which plays a 
central role in GC development (Rad et al., 2004). The combined prevalence of H. pylori 
infection and IL-1ǃ -511T genotype has a strong association with GC risk in both Latino and 
Chinese populations (Morgan et al., 2006; Feng et al., 2008). The IL-1ǃ -511T/T carrier status 
enhances hypermethylation of multiple CpG island loci and increases the risk for Hp-GC of 
non-cardiac type as an independent risk factor in a Chinese population (Li et al., 2007; Yoo 
et al., 2010). IL-1ǃ -511C allele is related with increased risk of AG and GC in Peru (Gehmert 
et al., 2009). IL-1ǃ -511C/C polymorphism enhances IL-1ǃ production in the antrum, and 
involves in the development of nHp-GC in North Indian (Kumar et al., 2009). In a Korean 
population, combined effects of H. pylori infection and IL-1ǃ -511C/-31T polymorphisms 
with enhanced mucosal IL-1ǃ production contribute to the development of intestinal-type 
GC (Chang et al., 2005). IL-1ǃ -511CC/-31TT variants also increase GC risk in a Chinese 
population, especially of those with H. pylori infection (Yang et al., 2004). Nevertheless, IL-
1ǃ -511/-31 alleles are not associated with GC risk in Japan and IL-1ǃ -511T-to-C genotype is 
not associated with GC in a multistep carcinogenesis model (Kato et al., 2001; Sugimoto et 
al., 2007). In addition, none of the variants of IL-1ǃ -511C>T, -31T>C, -1464G>C and -
3737C>T, is individually or in its haplotype configuration linked to GC in a Caucasian 
population (Wex et al., 2010).  
IL-1ǃ -31C/+3954T haplotypes are more likely detected with IM or dysplasia of the stomach 
and relate to GC risk in African Americans, but not in Caucasians, Swedes and Italians (Palli 
et al., 2005; Camargo et al., 2006; Persson et al., 2009; Zabaleta et al., 2011). In Mexico, IL-1ǃ -
31C allele increases high-grade dysplasia and is an independent risk factor for GC (Garza-
González et al., 2003). The IL-1ǃ -31CC carriers have an increased risk of intestinal-type GC 
among CagA-positive subjects, compared to those with IL-1ǃ -31TT. Among CagA-negative 
subjects, however, there is no mentioned association (Sicinschi et al., 2006). IL-1ǃ 1473C>G is 
significantly associated with GC among Koreans (Lee et al., 2004). In Japan, IL-1ǃ +3953 
polymorphism can influence the cancer risk of gastric corpus (Sakuma et al., 2005). Carriers 
of IL-1ǃ +3954T or IL-1RN2 heterozygote allele cause increased GC risk in a Costa Rican 
population, although IL-1ǃ -31, IL-1ǃ -511 and IL-10 polymorphisms do not (Alpízar-
Alpízar et al., 2005).  
IL-1RN1/2 genotype is significantly and independently associated with GC (Erzin et al., 2008). 
IL-1RN2 allele relates to GC especially in H. pylori-positive patients of an Omani Arab 
population (Al-Moundhri et al., 2006). In Italy, multivariate analyses have shown a notable 
increase in GC risk for the IL-1RN2 / IL-1ǃ -31T haplotype carriers (Palli et al., 2005). H. pylori-
infected individuals with carriers of IL-1RN2 show high risks for both intestinal and diffuse 
types of GC in Asia (Chen et al., 2004). IL-1RN2 and IL-1ǃ -511T may contribute to intestinal 
GC in the absence of concomitant H. pylori infection (Ruzzo et al., 2005). IL-1RN2/2 and IL-1ǃ -
31C genotypes relate to higher GC risk in Caucasians (Garza-González et al., 2003). The IL-
1RN2/2 genotype is strongly associated with early-stage GC, and involves in the development 
of nHp-GC in North Indian (Glas et al., 2004; Kumar et al., 2009). IL-1RN 2R/2R and Ex5-35C 
genotypes are related to an increased risk of Hp-GC of non-cardia type (Crusius et al., 2008). 
However, IL-1ǃ -511, IL-1RN and IL-2 polymorphisms do not significantly contribute to GC in 
Korean patients (Shin et al., 2008). In Mexico, IL-1RN2/2 is also not associated with either 
high-grade dysplasia or risk of GC (Garza-González et al., 2003). 
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As for subtypes of GC in Taiwanese Chinese, the high IL-10 producer genotype is 
significantly linked with the risk of cardia type or advanced stage (Wu et al., 2003). The 
ATA/GCC haplotype of IL-10 -1082/-819/-592 significantly increases GC risk compared 
with ATA/ATA haplotype (Sugimoto et al., 2007). The -1082G/-819C/-592C alleles (GCC 
haplotype) usually lead to higher mucosal IL-10 mRNA level than ATA haplotype and are 
associated with colonization by more virulent H. pylori strains of cagA (+), vacA s1 (+), and 
babA2 (+) (Rad et al., 2004). IL-10 -1082 AG+GG but not -819 or -592 polymorphisms, 
markedly increase GC risk in China, especially in patients with H. pylori infection (Xiao et 
al., 2009). In a low prevalence province of China, the -1082G* allele is related with 
significantly increased risk of Hp-GC, whereas the higher susceptibility to GC in -1082 
AG+GG genotype does not show a synergism with H. pylori status in another population of 
northern China (Bai et al., 2008). In Korean, the frequency of -1082G carriers is higher in 
diffuse-type GC or benign gastric ulcer (BGU), regardless of H. pylori infection (Kang et al., 
2009). Moreover, IL-10 -819CC and IL-1RN 9589TT genotypes are of inverse association with 
H. pylori seropositivity among cases with chronic AG, an established precursor of GC (Gao 
et al., 2009). The IL-10 819C allele is related with IM in H. pylori-positive subjects of a 
Singapore-Chinese population (Zhu et al., 2009).  
In H. pylori-infected Japanese, the frequency of -592AA homozygote showing concomitant 
carriage of HLA DRB1*0405-DQB1*0401 is notably higher in intestinal-type GC. In addition, 
the HLA class II and -592A/C polymorphism synergistically affect the susceptibility to GC 
(Ando et al., 2009). IL-10 -592C/A, IL-1ǃ +3954T/C and IL-1RN*2/L are individually 
associated with GC in Costa Rican regions, and a combination of these cytokine 
polymorphisms with H. pylori vacA s1b / m1 genotypes further increased the risk (Con et 
al., 2009). IL-10 -592/-1082 alleles are not linked with high-grade dysplasia or GC risk in a 
Mexican population, though relate to high GC risk in Caucasians; whereas carriers with two 
or more risk-associated alleles of IL-10 -592C, IL-1ǃ -31C and IL-1RN2 are at increased risk 
for intestinal-type GC in Mexico, compared to those with 0 or 1 mentioned allele (Garza-
González et al., 2003). In Korean, the presence of IL10 -592C/A as opposed to A/A is one of 
risk factors for IM. The -592CC is associated with more than doubling of the risk for 
intestinal-type GC. Furthermore, a synergistic effect has been observed between IL-10 -
592A/A and IL-8 -251A/A with respect to the development of GC or BGU (Kang et al., 
2009). IL-10 -819C and -592C alleles are associated with increased GC risk in Japan, but -1082 
polymorphism not (Sugimoto et al., 2007). The -819TT genotype relates to IM and non-
cardia GC in an Italian population (Zambon et al., 2005). 
Data from Korea have even suggested that the association between IL-10 genetic 
polymorphisms and GC risk is modified by soybean product intake (Ko et al., 2009). The 
combined effect between low intake of soybean products and -1082AG/GG, -819TC/CC or -
592GG/GA variants will increase the risk for GC. As for subgroups, the CCG haplotype has 
an increased risk of GC relative to ATA haplotype among subjects with low intake of 
soybean products (Ko et al., 2009). 
5.3 IL-4, IL-6 and IL-8 
There is a moderately increased risk for Hp-GC of non-cardia type in IL-4R -29429T variant 
(Crusius JB et al., 2008). In Taiwanese Chinese, a higher risk of developing cardia or diffuse-
type GC is observed for the carrier of IL-4 -590CT/CC genotype (Wu et al., 2003). IL-4 -168C 
and -590T alleles and IL-6 -174G/G haplotype significantly relate to the risk of non-cardia 
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GC (Sugimoto et al., 2010). The IL-6 -174G allele is markedly higher in patients with GC than 
those with chronic gastritis (Gatti et al., 2007).  
IL-8 -251A allele significantly increases the risk of gastric dysplasia in Venezuelan subjects, 
especially of those infected with CagA (+) H. pylori, which suggests a role of interactions 
between host and bacterial genetic factors in the development of precancerous lesions (Kato 
et al., 2006). Similarly in a Mexican population, the -251A genotype has a significant effect 
on the prevalence of dysplasia and may be related to distal GC, especially when H. pylori 
CagA is present (Garza-Gonzalez et al., 2007). IL-8 -251A/T allele and polymorphisms in 
vacA gene are involved in limiting the infection outcome to gastritis and peptic ulcer or in 
favoring cancer onset in Iranian patients (Kamali-Sarvestani et al., 2006). The -251T>A 
polymorphism is usually associated with higher IL-8 expression, severe neutrophil 
infiltration and increased risk of AG and GC in Japan, but not with GC risk in a Portuguese 
population (Taguchi et al., 2005; Canedo et al., 2008). The IL-8 -251A polymorphism may be 
associated with progression of AG in H. pylori-infected patients, and increase the risks for 
GC and gastric ulcer in Japanese people (Ohyauchi et al., 2005). The -251A/A genotype, 
which is more common in H. pylori-positive patients with GC or BGU than in H. pylori-
positive controls, increases the risk for upper-third location, diffuse, poorly differentiated, 
lymph node and liver metastasis, and p53-mutated subtypes of GC (Taguchi et al., 2005; 
Kang et al., 2009). The high-risk IL-8 -251T allele is related with >2-fold increased risk for 
GC of diffused and mixed types (Lee et al., 2005). In addition, the -251T/T genotype 
significantly relates to increased risk of GC with high frequency of microsatellite instability 
(Shirai et al., 2006).  
5.4 TNF 
Polymorphisms of TNF-ǂ -857TT and -1031TT, besides CD14, CXC chemokine receptor 2 
(CXCR2), IL-1 RI, NF-κB2, and TLR-4, have the potential to influence persistent H. pylori 
infection (Hamajima et al., 2003). TNF-ǂ -857T/-863A/-1031C alleles are associated with 
increased risks for gastric ulcer and GC in Japan (Sugimoto et al., 2007). In a Korean 
population, the -857C/T variant is independently and significantly related to an increased 
risk of GC regardless of smoking status. However, all haplotype-pairs including TCT or 
CCC of -863C/A and -1031T/C are linked with a higher GC risk only among smokers (Yang 
et al., 2009). TNF-ǂ -308 genotypes correlate to higher risk of GC in Caucasians, but not to 
high-grade dysplasia or increased risk of GC in Mexican population (Garza-González et al., 
2003). The -308A allele increases the risk for GC development but is only weakly associated 
with the early-stage diffuse-type GC (Glas et al., 2004). The -308G/A haplotype relates to an 
increased IL-8 expression and the susceptibility to GC in several studies. In Poland, GC risk 
is dramatically relevant to the TNF-ǂ -308G>A and IFN-Ǆ R2 Ex7-128C>T polymorphisms, 
but not to IL-1ǂ -889C>T and IL-12ǂ IVS2-798T>A, IVS2-701C>A and Ex7+277G>A variants 
(Hou et al., 2007). Risk of GC is also markedly elevated in Chinese subjects carrying the 
TNF-ǂ -308 AG genotype (Lu et al., 2005). In addition, polymorphisms in TNF-ǃ (*A and 
+252G/G) and HSP70-1 (*C and +190C/G) show a significant gene-dose effect as risk 
markers from preneoplastic lesions to GC in Mexican (Partida-Rodríguez et al., 2010). 
5.5 Other cytokine genes 
NOS2 -954G/C (especially -954GC+CC) polymorphism but not Ser608Leu is associated with 
higher risk of GC in a Brazilian population (Jorge et al., 2010). The iNOS C150T is related 
with the risk of Hp-GC, but not with gastric atrophy or H. pylori seropositivity in a Japanese 
population. Considering the location of GC, there are significant differences between the 
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controls and non-cardia group for iNOS -150C/T and C/T + T/T (Goto et al., 2006). The 
iNOS promoter polymorphism of long CCTTT repeat notably upregulates its mRNA level 
and leads to increased risk of intestinal-type GC in Japanese women, especially of those with 
IL-1ǃ -31 polymorphism and without smoking history (Tatemichi et al., 2005). 
In the high incidence Hexi area of Gansu Province in China, COX-2 -899G>C polymorphism 
may be a risk factor for GC, and the -899C carrier genotype and H. pylori infection possibly 
have a synergistic effect on GC. However, COX-2 587G>A is not related with GC risk (Zhu 
et al., 2011). COX-2 -1195AA polymorphism also plays an important role in developing GC 
in another high-risk Chinese population (Zhang et al., 2006). COX-2 -765G>C polymorphism 
might be a marker for genetic susceptibility to GC in northern India, regardless of H. pylori 
infection (Saxena et al., 2008). Moreover, the lymphotoxin-ǂ NcoI A/G heterozygous 
genotype correlates to H. pylori infection in noncardia GC patients of Chinese Han 
population (Li et al., 2005). And in Cauca population, the glutathione S-transferase M1 
homozygous deletion polymorphism is related to increased GC risk (Torres et al., 2004). 
6. Beneficial edge of the sword 
In recent years, increasing data have indicated that patients with Hp-GC prospectively have 
a better outlook than those with nHp-GC (Meimarakis et al., 2006; Marrelli et al., 2009). H. 
pylori infection must play certain roles as the other edge of the sword, which is beneficial for 
the host and counteracts its harmfulness in pathological lesions including gastritis, GC, and 
lymphoma. However, up to date, the corresponding studies and results are still limited 
because of multiple influencing factors including traditional unilateral opinions. 
The positive interaction between H. pylori and the host should be the radical factor in 
leading to changes of local and system immune responses. There is a high H. pylori 
prevalence but a low GC risk in H. pylori-infected than in uninfected Mexican children, 
which may be attributed to significantly higher infiltration of macrophages and T and B 
cells, a balanced increase of CD4, CD8, and CD20 lymphocytes, but decreased levels of 
activated mast cells, neutrophil and mononuclear cells (Muñoz et al., 2007). During H. pylori 
infection, both the number of local CD4 (+) T cells and MHC II expression by the GECs 
increase, and GECs can process and present antigens to CD4 (+) T cells as a new kind of 
local antigen presenting cells (APC) (Barrera et al., 2002). Therefore, H. pylori infection in the 
host may alter natural immune mechanisms against cancer.  
The humeral immune response induced by H. pylori is predominately IgG1 subclass 
(suggestive of a Th2 response) and likely protects against the development of GC, although 
it is not essential for bacterial eradication (Segal et al., 2001). As reported, the antibody level 
of anti- Thomsen-Friedenreich antigen (TAg) in GC patients is significantly lower than that 
in normal blood donors (Klaamas et al., 2002). However, TAg-specific IgG immune response 
is up-regulated exclusively in H. pylori-infected individuals, which may contribute to the 
significantly better survival of Hp-GC patients at early stage than that of nHp-GC ones at 
the same stage. Better survival is also noted in H. pylori seropositive IgM strong responders 
at approximately 40-60 months of observation, though the anti-T IgM level is not 
significantly related to the survival (Kurtenkov et al., 2003). In addition, the stimulation of 
H. pylori-related autoantibodies in antigen processing and presentation and subsequent T-
cell activation and proliferation improves host immune status. On the other hand, in an 
autoimmune response, autoantibodies can induce the cross-reaction against those localized 
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or circulating GC cells, which are characterized by mimic or absorbed H. pylori antigens, and 
lead to the killing and even suppressing of metastasis of cancer cells (Xue et al., 2008). Thus, 
it is hypothesized that autoimmune responses induced by H. pylori components may help 
improve the prognosis of GC patients. 
Several models, including delayed type hypersensitivity in immune mice, and spontaneous 
clearance of H. pylori from IL-10 and phagocyte oxidase mice, provide evidence that severe 
inflammation may be sufficient to eradicate the germ (Blanchard et al., 2004). H. pylori LPS 
can dramatically initiate inflammatory responses and cause severe pathological changes not 
only in vitro but also in vivo. However, increased levels of TNF-ǂ and IL-10, as well as a 
strong antigen specific Th1 response including, IFN-Ǆ, IL-2 and high IgG2a serum titers are 
simultaneously observed in mice inoculated with H. pylori LPS+ sonicate. Mice that received 
LPS- sonicate are strongly Th2 biased in their immune response, with significantly more IL-4 
than IFN-Ǆ and serum IgG1 titers higher than IgG2a (Taylor et al., 2006). Accordingly, H. 
pylori-induced inflammatory responses potentially have positive functions in resisting 
certain cancer-advancement-related biological processes post the development of GC and 
showing better outlook in those patients, although they have played fundamental roles 
during the phase of cancer formation.  
Interestingly, the COX-2 expression induced by H. pylori still seems to be able to attenuate 
the degree of AG, the initial event of GC, though it plays a role in gastric carcinogenesis 
(Hahm et al., 2002). COX-2-dependent PGE2 also shows a protective effect during the 
oncogenic process of Hp-GC in that it can prevent H. pylori-induced gastric preneoplasia 
and reverse preexisting lesions by suppressing IFN-Ǆ expression (Toller et al., 2010). As 
confirmed, the protective effect is always accompanied by increased bacterial colonization in 
models, which is attributed to the IL-2-dependent immunosuppressive effects of PGE2 on 
CD4 (+) Th1 cells in migration, proliferation and cytokine secretion. Therefore, PGE2 has an 
important immunomodulatory role during H. pylori infection, preventing excessive local 
immune responses and the associated immunopathology by inhibiting the effector functions 
of pathogenic Th1 cells (Toller et al., 2010). 
Certain genetic and phenotypic polymorphisms also show beneficial effects in improving 
the prognosis of GC patients, which might differ in various populations and need further 
confirmation. IL-6 -572G carrier is found to have a protective effect against IM 
development as compared with C/C (Kim et al., 2008). IL-8 -251AA genotype confers a 
decreased risk for Hp-GC of non-cardia type, mainly of the intestinal type (Crusius et al., 
2008). IL-10 -592C/C is an independent factor associated with a decreased risk of 
intestinal-type GC by multivariate analysis (Kang et al., 2009). When analyzed together 
with host genetic factors, the presence of the IL-1ǃ -31TT genotype emerges as a protective 
factor against gastric malignant disorders (Erzin et al., 2008). Based on a review of 25 case-
control studies in Caucasian, Asian and African populations, IL-1ǃ and NAT1 variants are 
most consistently associated with increased GC risk, which may account for up to 48% of 
attributable risk of GC, but HLA-DQ, TNF and CYP2E polymorphisms may confer certain 
protection against GC (González et al., 2002). However, a comprehensive analysis of 207 
SNPs of 11 Cytokine genes including IL-1ǂ, IL-1ǃ, IL-1RN, IL-4, IL-4R, IL-8, IL-10, IL-12, 
TNF-ǂ, TNF-ǃ, and IFN-Ǆ, has revealed that just variations in IL-4 (984 and 2983 AA/GA) 
and IL-1RN (-1102 and 6110 CG/GA) diplotypes are negatively associated with the risk of 
Hp-GC (Seno et al., 2007). 
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The majority of GC relates to chronic inflammation induced by H. pylori infection, in which 
many bacterial virulence factors including Cag PAI, VacA, OMP, LPS, urease, IceA, and 
flagella components participate with fundamental roles through a complex network of 
inflammatory cytokines, multiple signalling pathways, and even some genetic or 
phenotypic polymorphisms of the host. Gastric carcinogenesis, especially of the intestinal-
type tumor, is a multistep process of mucosal alterations leading from gastritis via glandular 
atrophy, IM and dysplasia to invasive carcinoma (Bornschein et al., 2010). There is a 
potential ‘point of no return’ during this process, which means a situation when certain 
alterations are no longer reversible by H. pylori eradication and progression to GC have to 
continue (Vieth et al., 2006; Bornschein et al., 2010). Thus, the gastric carcinogenesis is 
actually divided into two phases; one is of reversible pre-the-‘point of no return’, and the 
other is of irreversible post-the-‘point of no return’. During the first phase, H. pylori works 
with more roles as a confirmed carcinogen according to traditional opinion; whereas in the 
second phase, the inflammation has been switched to H. pylori-independent carcinogenesis 
with GC as the destination. 
Considering the host-bacterium cross-talk background and described double functions of 
both inflammatory / immune responses and genetic / phenotypic polymorphisms, a novel 
angle should be adopted to analyze the roles of H. pylori as a double-edged sword in GC. H. 
pylori is more harmful in promoting carcinogenesis prior to the ‘point of no return’, 
however, may be more beneficial for improving the host outlook post the development of 
GC. Based on this theory, H. pylori eradication may be performed at proper stage to protect 
against GC, and more efficient vaccines of prophylaxis and therapeutic ones might be 
designed and used to prevent the advancement of GC and improve the prognosis, which 
needs further confirmation by large from-bench-to-bed studies. 
8. Acknowledgement 
This work is supported by a grant from the National Natural Science Foundation of China 
(No.30901733). 
9. References 
Akhiani AA. The role of type-specific antibodies in colonization and infection by Helicobacter 
pylori. Curr Opin Infect Dis. 2005;18(3):223-7. 
Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, Al-
Yahyaee SA, Grant CS. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor 
antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab 
population. Gastric Cancer. 2006;9(4):284-90. 
Alpízar-Alpízar W, Pérez-Pérez GI, Une C, Cuenca P, Sierra R. Association of interleukin-1B 
and interleukin-1RN polymorphisms with gastric cancer in a high-risk population 
of Costa Rica. Clin Exp Med. 2005;5(4):169-76. 
Ando T, Ishikawa T, Kato H, Yoshida N, Naito Y, Kokura S, Yagi N, Takagi T, Handa O, 
Kitawaki J, Nakamura N, Hasegawa G, Fukui M, Imamoto E, Nakamura C, 
Oyamada H, Isozaki Y, Matsumoto N, Nagao Y, Okita M, Nakajima Y, Kurokawa 
M, Nukina M, Ohta M, Mizuno S, Ogata M, Obayashi H, Park H, Kitagawa Y, 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
280 
Nakano K, Yoshikawa T. Synergistic effect of HLA class II loci and cytokine gene 
polymorphisms on the risk of gastric cancer in Japanese patients with Helicobacter 
pylori infection. Int J Cancer. 2009;125(11):2595-602. 
Appelmelk BJ, Vandenbroucke-Grauls CMJE. Lipopolysaccharide Lewis Antigens. In: 
Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and 
Genetics. Washington (DC): ASM Press; 2001. Chapter 35. 
Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, Sparwasser T, Müller A. Tolerance 
rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. 
Gastroenterology. 2011;140(1):199-209. 
Asim M, Chaturvedi R, Hoge S, Lewis ND, Singh K, Barry DP, Algood HS, de Sablet T, 
Gobert AP, Wilson KT. Helicobacter pylori induces ERK-dependent formation of a 
phospho-c-Fos c-Jun activator protein-1 complex that causes apoptosis in 
macrophages. J Biol Chem. 2010;285(26):20343-57. 
Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in 
vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA 
types with cytotoxin production and peptic ulceration. J Biol Chem. 
1995;270(30):17771-7. 
Axsen WS, Styer CM, Solnick JV. Inhibition of heat shock protein expression by Helicobacter 
pylori. Microb Pathog. 2009;47(4):231-6. 
Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR. Helicobacter pylori CagA induces a 
transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad 
Sci USA 2005; 102(45): 16339-44.  
Bai XL, Sun LP, Liu J, Chen W, Zhang Y, Yuan Y. [Correlation of interleukin-10-1082G/a 
single nucleotide polymorphism to the risk of gastric cancer in north China: a case-
control study]. Ai Zheng. 2008;27(1):35-40. 
Baldari CT, Lanzavecchia A, Telford JL. Immune subversion by Helicobacter pylori. Trends 
Immunol 2005; 26(4): 199-207. 
Barrera C, Espejo R, Reyes VE. Differential glycosylation of MHC class II molecules on 
gastric epithelial cells: implications in local immune responses. Hum Immunol. 
2002;63(5):384-93. 
Beales IL. Effect of interlukin-1beta on proliferation of gastric epithelial cells in culture. BMC 
Gastroenterol. 2002;2:7.  
Becher D, Deutscher ME, Simpfendorfer KR, Wijburg OL, Pederson JS, Lew AM, Strugnell 
RA, Walduck AK. Local recall responses in the stomach involving reduced 
regulation and expanded help mediate vaccine-induced protection against 
Helicobacter pylori in mice. Eur J Immunol. 2010;40(10):2778-90. 
Beswick EJ, Reyes VE. Macrophage migration inhibitory factor and interleukin-8 produced 
by gastric epithelial cells during Helicobacter pylori exposure induce expression and 
activation of the epidermal growth factor receptor. Infect Immun. 2008;76(7):3233-
40. 
Blanchard TG, Drakes ML, Czinn SJ. Helicobacter infection: pathogenesis. Curr Opin 
Gastroenterol. 2004;20(1):10-5. 
Bornschein J, Kandulski A, Selgrad M, Malfertheiner P. From gastric inflammation to gastric 
cancer. Dig Dis. 2010;28(4-5):609-14. 
Bronte-Tinkew DM, Terebiznik M, Franco A, Ang M, Ahn D, Mimuro H, Sasakawa C, 
Ropeleski MJ, Peek RM Jr, Jones NL. Helicobacter pylori cytotoxin-associated gene A 
www.intechopen.com
 
A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
281 
activates the signal transducer and activator of transcription 3 pathway in vitro and 
in vivo. Cancer Res. 2009;69(2):632-9. 
Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. Helicobacter felis eradication 
restores normal architecture and inhibits gastric cancer progression in C57BL/6 
mice. Gastroenterology. 2005;128(7):1937-52. 
Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, Piazuelo MB, 
Sicinschi L, Zabaleta J, Schneider BG. Interleukin-1beta and interleukin-1 receptor 
antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer 
Epidemiol Biomarkers Prev. 2006;15(9):1674-87. 
Canedo P, Castanheira-Vale AJ, Lunet N, Pereira F, Figueiredo C, Gioia-Patricola L, Canzian 
F, Moreira H, Suriano G, Barros H, Carneiro F, Seruca R, Machado JC. The 
interleukin-8-251*T/*A polymorphism is not associated with risk for gastric 
carcinoma development in a Portuguese population. Eur J Cancer Prev. 
2008;17(1):28-32. 
Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-Induced invasion and angiogenesis of 
gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and 
promoter regulation. J Immunol. 2005;175(12):8242-52. 
Chang YJ, Wu MS, Lin JT, Sheu BS, Muta T, Inoue H, Chen CC. Induction of 
cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter 
pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. 
Mol Pharmacol. 2004;66(6):1465-77. 
Chang YW, Jang JY, Kim NH, Lee JW, Lee HJ, Jung WW, Dong SH, Kim HJ, Kim BH, Lee JI, 
Chang R. Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-
1beta cytokine in Korean patients with gastric cancer. Int J Cancer. 2005;114(3):465-
71.  
Chen A, Li CN, Hsu PI, Lai KH, Tseng HH, Hsu PN, Lo GH, Lo CC, Lin CK, Hwang IR, 
Yamaoka Y, Chen HC. Risks of interleukin-1 genetic polymorphisms and 
Helicobacter pylori infection in the development of gastric cancer. Aliment 
Pharmacol Ther. 2004;20(2):203-11. 
Chen CN, Hsieh FJ, Cheng YM, Chang KJ, Lee PH. Expression of inducible nitric oxide 
synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human 
gastric cancer. J Surg Oncol. 2006;94(3):226-33. 
Cho SO, Lim JW, Kim KH, Kim H. Involvement of Ras and AP-1 in Helicobacter pylori-
induced expression of COX-2 and iNOS in gastric epithelial AGS cells. Dig Dis Sci. 
2010;55(4):988-96. 
Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. Helicobacter pylori 
CagA protein targets the c-Met receptor and enhances the motogenic response. J 
Cell Biol. 2003;161(2):249-55. 
Con SA, Takeuchi H, Con-Chin GR, Con-Chin VG, Yasuda N, Con-Wong R. Role of bacterial 
and genetic factors in gastric cancer in Costa Rica. World J Gastroenterol. 
2009;15(2):211-8. 
Coombs N, Sompallae R, Olbermann P, Gastaldello S, Göppel D, Masucci MG, Josenhans C. 
Helicobacter pylori affects the cellular deubiquitinase USP7 and ubiquitin-regulated 




Gastric Carcinoma - Molecular Aspects and Current Advances 
 
282 
Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, 
Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, 
Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, 
Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, 
Binghan S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, 
Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, 
Rinaldi S, Ferrari P, Riboli E, González CA. Cytokine gene polymorphisms and the 
risk of adenocarcinoma of the stomach in the European prospective investigation 
into cancer and nutrition (EPIC-EURGAST). Ann Oncol. 2008;19(11):1894-902. 
D'Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Helicobacter pylori, T cells and 
cytokines: the "dangerous liaisons". FEMS Immunol Med Microbiol. 2005;44(2):113-
9. 
D'Elios MM, Montecucco C, de Bernard M. VacA and HP-NAP, Ying and Yang of 
Helicobacter pylori-associated gastric inflammation. Clin Chim Acta. 2007;381(1):32-
8. 
Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009;49(5 
Suppl):S56-60.  
Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, Li HL, Rothman N, Zheng W, Chow 
WH, Abnet CC. Urinary prostaglandin E2 metabolite and gastric cancer risk in the 
Shanghai women's health study. Cancer Epidemiol Biomarkers Prev. 
2009;18(11):3075-8. 
Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997;10(4):720-41.  
Ernst PB, Pappo J. T-cell-mediated mucosal immunity in the absence of antibody: lessons 
from Helicobacter pylori infection. Acta Odontol Scand. 2001;59(4):216-21. 
Erzin Y, Koksal V, Altun S, Dobrucali A, Aslan M, Erdamar S, Goksel S, Dirican A, 
Kocazeybek B. Role of host interleukin 1beta gene (IL-1B) and interleukin 1 
receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in 
Helicobacter pylori-positive Turkish patients with dyspepsia. J Gastroenterol. 
2008;43(9):705-10. 
Feng Y, Zhang J, Dai L, Zhang J, Wang P, Zang J, Li Y, Wang K. Inflammatory cytokine gene 
polymorphisms in gastric cancer cases' and controls' family members from Chinese 
areas at high cancer prevalence. Cancer Lett. 2008;270(2):250-9. 
Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint 
W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simões M. Helicobacter pylori and 
interleukin 1 genotyping: an opportunity to identify high-risk individuals for 
gastric carcinoma. J Natl Cancer Inst. 2002;94(22):1680-7. 
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi 
S, Asaka M; Japan Gast Study Group. Effect of eradication of Helicobacter pylori on 
incidence of metachronous gastric carcinoma after endoscopic resection of early 
gastric cancer: an open-label, randomized controlled trial. Lancet 2008; 
372(9636):392-7. 
Futagami S, Tatsuguchi A, Hiratsuka T, Shindo T, Horie A, Hamamoto T, Ueki N, Kusunoki 
M, Miyake K, Gudis K, Tsukui T, Sakamoto C. Monocyte chemoattractant protein 1 
and CD40 ligation have a synergistic effect on vascular endothelial growth factor 




A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
283 
Galamb O, Gyõrffy B, Sipos F, Dinya E, Krenács T, Berczi L, Szõke D, Spisák S, Solymosi N, 
Németh AM, Juhász M, Molnár B, Tulassay Z. Helicobacter pylori and antrum 
erosion-specific gene expression patterns: the discriminative role of CXCL13 and 
VCAM1 transcripts. Helicobacter. 2008;13(2):112-26. 
Gao L, Weck MN, Nieters A, Brenner H. Inverse association between a pro-inflammatory 
genetic profile and Helicobacter pylori seropositivity among patients with chronic 
atrophic gastritis: enhanced elimination of the infection during disease 
progression? Eur J Cancer. 2009;45(16):2860-6. 
Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-
Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, 
Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of 
distal gastric cancer. BMC Cancer. 2007;7:70. 
Garza-González E, Hold G, Pérez-Pérez GI, Bosques-Padilla FJ, Tijerina-Menchaca R, 
Maldonado-Garza HJ, el-Omar E. [Role of polymorphism of certain cytokines in 
gastric cancer in Mexico. Preliminary results] Rev Gastroenterol Mex. 
2003;68(2):107-12. 
Gatti LL, Burbano RR, Zambaldi-Tunes M, de-Lábio RW, de Assumpção PP, de Arruda 
Cardoso-Smith M, Marques-Payão SL. Interleukin-6 polymorphisms, Helicobacter 
pylori infection in adult Brazilian patients with chronic gastritis and gastric 
adenocarcinoma. Arch Med Res. 2007;38(5):551-5. 
Gebert B, Fischer W, Haas R. The Helicobacter pylori vacuolating cytotoxin: from cellular 
vacuolation to immunosuppressive activities. Rev Physiol Biochem Pharmacol. 
2004;152:205-20. 
Gehmert S, Velapatiño B, Herrera P, Balqui J, Santivañez L, Cok J, Vargas G, Combe J, 
Passaro DJ, Wen S, Meyer F, Berg DE, Gilman RH. Interleukin-1 beta single-
nucleotide polymorphism's C allele is associated with elevated risk of gastric cancer 
in Helicobacter pylori-infected Peruvians. Am J Trop Med Hyg. 2009;81(5):804-10. 
Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehlke S, Classen M, Prinz 
C. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding 
adhesin. Proc Natl Acad Sci USA. 1999; 96(22):12778-83. 
Glas J, Török HP, Schneider A, Brünnler G, Kopp R, Albert ED, Stolte M, Folwaczny C. 
Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric 
cancer. J Clin Oncol. 2004;22(23):4746-52. 
González CA, Sala N, Capellá G. Genetic susceptibility and gastric cancer risk. Int J Cancer. 
2002;100(3):249-60.  
Goto Y, Ando T, Naito M, Goto H, Hamajima N. Inducible nitric oxide synthase 
polymorphism is associated with the increased risk of differentiated gastric cancer 
in a Japanese population. World J Gastroenterol. 2006;12(39):6361-5. 
Grebowska A, Moran AP, Matusiak A, Bak-Romaniszyn L, Czkwianianc E, Rechciński T, 
Walencka M, Płaneta-Małecka I, Rudnicka W, Chmiela M. Anti-phagocytic activity 
of Helicobacter pylori lipopolysaccharide (LPS)--possible modulation of the innate 
immune response to these bacteria. Pol J Microbiol. 2008;57(3):185-92. 
Guo T, Qian JM, Zhang JZ, Li XB, Zhao YQ. [Effects of Helicobacter pylori and Helicobacter 
pylori-related cytokines on apoptosis of gastric epithelial cells and mechanisms 
thereof] Zhonghua Yi Xue Za Zhi. 2006;86(38):2670-3. 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
284 
Hahm KB, Lim HY, Sohn S, Kwon HJ, Lee KM, Lee JS, Surh YJ, Kim YB, Joo HJ, Kim WS, 
Cho SW. In vitro evidence of the role of COX-2 in attenuating gastric inflammation 
and promoting gastric carcinogenesis. J Environ Pathol Toxicol Oncol. 
2002;21(2):165-76. 
Hamajima N. Persistent Helicobacter pylori infection and genetic polymorphisms of the host. 
Nagoya J Med Sci. 2003;66(3-4):103-17. 
Hennig EE, Mernaugh R, Edl J, Cao P, Cover TL. Heterogeneity among Helicobacter pylori 
strains in expression of the outer membrane protein BabA. Infect Immun 2004; 
72(6): 3429-35. 
Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M. SHP-2 
tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. 
Science 2002;295(5555):683-6. 
Höcker M, Hohenberġer P. Helicobacter pylori virulence factors--one part of a big picture. 
Lancet 2003; 362 (9391):1231-3. 
Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, Yeager M, Chanock SJ, 
Zatonski W, Sobin LH, Lissowska J, Fraumeni JF Jr, Chow WH. Polymorphisms in 
Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis. 
2007;28(1):118-23. 
Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship 
between cagA seropositivity and gastric cancer. Gastroenterology 2003;125(6):1636–
44. 
Huang L, Zhang KL, Li H, Chen XY, Kong QY, Sun Y, Gao X, Guan HW, Liu J. Infrequent 
COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, 
China. Hum Pathol. 2006;37(12):1557-67. 
Hussain MA, Naveed SA, Sechi LA, Ranjan S, Alvi A, Ahmed I, Ranjan A, Mukhopadhyay 
S, Ahmed N. Isocitrate dehydrogenase of Helicobacter pylori potentially induces 
humoral immune response in subjects with peptic ulcer disease and gastritis. PLoS 
One. 2008;3(1):e1481. 
Hynes SO, Keenan JI, Ferris JA, Annuk H, Moran AP. Lewis epitopes on outer membrane 
vesicles of relevance to Helicobacter pylori pathogenesis. Helicobacter. 
2005;10(2):146-56. 
Ierardi E, Di Leo A, Barone M, Marangi S, Burattini O, Panarese A, Margiotta M, Francavilla 
R, Panella C, Francavilla A, Cuomo R. Tumor necrosis factor alpha and apoptosis in 
Helicobacter pylori related progressive gastric damage: a possible mechanism of 
immune system involvement in epithelial turnover regulation. Immunopharmacol 
Immunotoxicol. 2003;25(2):203-11. 
Inoue K, Shiota S, Yamada K, Gotoh K, Suganuma M, Fujioka T, Ahmed K, Iha H, Nishizono 
A.  Evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of 
Helicobacter pylori as a prophylactic vaccine antigen. Helicobacter. 2009;14(5):135-43. 
International Agency for Research on Cancer. Cancer incidence in five continents. IARC Sci 
Publ 2002;VIII:1-781. 
International Agency for Research on Cancer. Infection with Helicobacter pylori. In: IARC 
monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver 
flukes and Helicobacter pylori. Lyon: IARC,1994; 61:177-244. 
www.intechopen.com
 
A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
285 
Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Boussioutas A, 
Robb L, Giraud AS. Augmented gp130-mediated cytokine signalling accompanies 
human gastric cancer progression. J Pathol. 2007;213(2):140-51. 
Jang TJ. The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori 
gastritis and gastric cancer. Pathol Res Pract. 2010;206(1):34-8.  
Jorge YC, Duarte MC, Silva AE. Gastric cancer is associated with NOS2 -954G/C 
polymorphism and environmental factors in a Brazilian population. BMC 
Gastroenterol. 2010;10:64. 
Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K. 
Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of 
human gastric carcinoma. Anticancer Res. 2005;25(2A):709-13.  
Kamali-Sarvestani E, Bazargani A, Masoudian M, Lankarani K, Taghavi AR, Saberifiroozi 
M. Association of H pylori cagA and vacA genotypes and IL-8 gene 
polymorphisms with clinical outcome of infection in Iranian patients with 
gastrointestinal diseases. World J Gastroenterol. 2006;12(32):5205-10. 
Kandulski A, Malfertheiner P, Wex T. Role of regulatory T-cells in H. pylori-induced gastritis 
and gastric cancer. Anticancer Res. 2010;30(4):1093-103. 
Kang JM, Kim N, Lee DH, Park JH, Lee MK, Kim JS, Jung HC, Song IS. The effects of genetic 
polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced 
gastroduodenal diseases in Korea. J Clin Gastroenterol. 2009;43(5):420-8. 
Kassai K, Yoshikawa T, Yoshida N, Hashiramoto A, Kondo M, Murase H. Helicobacter pylori 
water extract induces interleukin-8 production by gastric epithelial cells. Dig Dis 
Sci. 1999;44(2):237-42. 
Katayama Y, Takahashi M, Kuwayama H. Helicobacter pylori causes runx3 gene methylation 
and its loss of expression in gastric epithelial cells, which is mediated by nitric 
oxide produced by macrophages. Biochem Biophys Res Commun. 2009;388(3):496-
500. 
Kato I, van Doorn LJ, Canzian F, Plummer M, Franceschi S, Vivas J, Lopez G, Lu Y, Gioia-
Patricola L, Severson RK, Schwartz AG, Muñoz N. Host-bacterial interaction in the 
development of gastric precancerous lesions in a high risk population for gastric 
cancer in Venezuela. Int J Cancer. 2006;119(7):1666-71. 
Kato S, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the 
interleukin-1 beta genetic polymorphism and gastric cancer risk in Japanese. J 
Gastroenterol. 2001;36(10):696-9. 
Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H. 
Preoperative serum interleukin-18 level as a postoperative prognostic marker in 
patients with gastric carcinoma. Cancer. 2001;92(8):2050-5. 
Keep S, Borlace G, Butler R, Brooks D. Role of immune serum in the killing of Helicobacter 
pylori by macrophages. Helicobacter. 2010;15(3):177-83. 
Kidd M, Peek RM, Lastovica AJ, Israel DA, Kummer AF, Louw JA. Analysis of iceA 
genotypes in South African Helicobacter pylori strains and relationship to clinically 
significant disease. Gut. 2001;49(5):629-35. 
Kim N, Park YS, Cho SI, Lee HS, Choe G, Kim IW, Won YD, Park JH, Kim JS, Jung HC, Song 
IS. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a 




Gastric Carcinoma - Molecular Aspects and Current Advances 
 
286 
Klaamas K, Held M, Wadström T, Lipping A, Kurtenkov O. IgG immune response to 
Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and 
immunoblotting. Int J Cancer. 1996;67(1):1-5. 
Klaamas K, Kurtenkov O, Rittenhouse-Olson K, Brjalin V, Miljukhina L, Shljapnikova L, 
Engstrand L. Expression of tumor-associated Thomsen-Friedenreich antigen (T Ag) 
in Helicobacter pylori and modulation of T Ag specific immune response in infected 
individuals. Immunol Invest. 2002;31(3-4):191-204. 
Klaamas K, Kurtenkov O, von Mensdorff-Pouilly S, Shljapnikova L, Miljukhina L, Brjalin V, 
Lipping A. Impact of Helicobacter pylori infection on the humoral immune response 
to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. 
Immunol Invest. 2007;36(4):371-86. 
Ko KP, Park SK, Cho LY, Gwack J, Yang JJ, Shin A, Kim CS, Kim Y, Kang D, Chang SH, Shin 
HR, Yoo KY. Soybean product intake modifies the association between interleukin-
10 genetic polymorphisms and gastric cancer risk. J Nutr. 2009;139(5):1008-12. 
Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, Kajiyama G, Talley NJ. 
Helicobacter pylori infection and gastric neoplasia: correlations with histological 
gastritis and tumor histology. Am J Gastroenterol. 1998;93(8):1271-6. 
Konturek PC, Kania J, Kukharsky V, Ocker S, Hahn EG, Konturek SJ. Influence of gastrin on 
the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related 
proteins in gastric epithelial cells. J Physiol Pharmacol. 2003;54(1):17-32. 
Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric 
cancerogenesis. J Physiol Pharmacol. 2009;60(3):3-21. 
Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, Karczewska 
E, Marlicz K, Stachura J, Hahn EG. Expression of hepatocyte growth factor, 
transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and 
gastrin in human gastric cancer. Aliment Pharmacol Ther. 2001;15(7):989-99. 
Konturek SJ, Starzynska T, Konturek PC, Karczewska E, Marlicz K, Lawniczak M, 
Jaroszewicz-Heigelman H, Bielanski W, Hartwich A, Ziemniak A, Hahn EG. 
Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid 
secretion in gastric cancer. Scand J Gastroenterol. 2002;37(8):891-8. 
Kumar S, Kumar A, Dixit VK. Evidences showing association of interleukin-1B 
polymorphisms with increased risk of gastric cancer in an Indian population. 
Biochem Biophys Res Commun. 2009;387(3):456-60. 
Kurtenkov O, Klaamas K, Sergeyev B, Chuzmarov V, Miljukhina L, Shljapnikova L. Better 
survival of Helicobacter pylori infected patients with early gastric cancer is related to 
a higher level of Thomsen-Friedenreich antigen-specific antibodies. Immunol 
Invest. 2003;32(1-2):83-93. 
Lamarque D, Tran Van Nhieu J, Breban M. [What are the gastric modifications induced by 
acute and chronic Helicobacter pylori infection?] Gastroenterol Clin Biol. 2003;27(3 Pt 
2):391-400. 
Lee IO, Kim JH, Choi YJ, Pillinger MH, Kim SY, Blaser MJ, Lee YC. Helicobacter pylori CagA 
phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT 




A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
287 
Lee KA, Ki CS, Kim HJ, Sohn KM, Kim JW, Kang WK, Rhee JC, Song SY, Sohn TS. Novel 
interleukin 1beta polymorphism increased the risk of gastric cancer in a Korean 
population. J Gastroenterol. 2004;39(5):429-33. 
Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ, Lin YP, Sheu ML, Li CP, Chang FY, Chao Y, 
Yen SH, Lee SD. The -251T allele of the interleukin-8 promoter is associated with 
increased risk of gastric carcinoma featuring diffuse-type histopathology in 
Chinese population. Clin Cancer Res. 2005;11(18):6431-41. 
Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, Chung SC, Sung JJ. Cyclooxygenase-
2 upregulates vascular endothelial growth factor expression and angiogenesis in 
human gastric carcinoma. Int J Oncol. 2003;23(5):1317-22. 
Lewis ND, Asim M, Barry DP, Singh K, de Sablet T, Boucher JL, Gobert AP, Chaturvedi R, 
Wilson KT. Arginase II restricts host defense to Helicobacter pylori by attenuating 
inducible nitric oxide synthase translation in macrophages. J Immunol. 
2010;184(5):2572-82. 
Li C, Xia B, Yang Y, Li J, Xia HH. TNF gene polymorphisms and Helicobacter pylori infection 
in gastric carcinogenesis in Chinese population. Am J Gastroenterol. 
2005;100(2):290-4. 
Li C, Xia HH, Xie W, Hu Z, Ye M, Li J, Cheng H, Zhang X, Xia B. Association between 
interleukin-1 gene polymorphisms and Helicobacter pylori infection in gastric 
carcinogenesis in a Chinese population. J Gastroenterol Hepatol. 2007;22(2):234-9. 
Li Q, Liu N, Shen B, Zhou L, Wang Y, Wang Y, Sun J, Fan Z, Liu RH. Helicobacter pylori 
enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signalling pathway in 
MKN45 cells. Cancer Lett. 2009;278(1):97-103. 
Lin JT, Wang JT, Wang TH, Wu MS, Chen CJ. Helicobacter pylori infection in early and 
advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese 
patients. Hepatogastroenterology. 1993;40(6):596-9. 
Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-
1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer 
in a Chinese population. Carcinogenesis. 2005;26(3):631-6. 
Lundin BS, Enarsson K, Kindlund B, Lundgren A, Johnsson E, Quiding-Järbrink M, 
Svennerholm AM. The local and systemic T-cell response to Helicobacter pylori in 
gastric cancer patients is characterised by production of interleukin-10. Clin 
Immunol. 2007;125(2):205-13. 
Manojlovic N, Babic D, Filipovic-Ljeshovic I, Pilcevic D. Anti Helicobacter pylori IgG and IgA 
response in patients with gastric cancer and chronic gastritis. 
Hepatogastroenterology. 2008;55(82-83):807-13. 
Manojlovic N, Nikolic L, Pilcevic D, Josifovski J, Babic D. Systemic humoral anti-Helicobacter 
pylori immune response in patients with gastric malignancies and benign 
gastroduodenal disease. Hepatogastroenterology. 2004;51(55):282-4. 
Marotti B, Rocco A, De Colibus P, Compare D, de Nucci G, Staibano S, Tatangelo F, Romano 
M, Nardone G. Interleukin-13 mucosal production in Helicobacter pylori-related 
gastric diseases. Dig Liver Dis. 2008;40(4):240-7. 
Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, Vindigni C, Santucci A, 
Figura N, Roviello F. Negative Helicobacter pylori status is associated with poor 
prognosis in patients with gastric cancer. Cancer 2009;115(10):2071-80. 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
288 
Matysiak-Budnik T & Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J 
Cancer 2006; 42: 708-16. 
Mbulaiteye SM, Gold BD, Pfeiffer RM, Brubaker GR, Shao J, Biggar RJ, Hisada M. H. pylori-
infection and antibody immune response in a rural Tanzanian population. Infect 
Agent Cancer. 2006; 1:3. 
McGee DJ, Mobley HL. Pathogenesis of Helicobacter pylori infection. Curr Opin 
Gastroenterol. 2000;16(1):24-31.  
McNamara D, El-Omar E. Helicobacter pylori infection and the pathogenesis of gastric cancer: 
a paradigm for host-bacterial interactions. Dig Liver Dis. 2008;40(7):504-9. 
Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, Stolte M, Jauch KW, Hatz 
RA. Helicobacter pylori as a prognostic indicator after curative resection of gastric 
carcinoma: a prospective study. Lancet Oncol 2006; 7(3): 211-22. 
Mimuro H, Suzuki T, Tanaka J, Asahi M, Haas R, Sasakawa C. Grb2 is a key mediator of 
Helicobacter pylori CagA protein activities. Mol Cell. 2002; 10(4):745-55. 
Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K. Expression of UreI is 
required for intragastric transit and colonization of gerbil gastric mucosa by 
Helicobacter pylori. Res Microbiol. 2002;153(10):659-66.  
Moran AP. The role of endotoxin in infection: Helicobacter pylori and Campylobacter jejuni. 
Subcell Biochem. 2010;53:209-40.  
Moran, AP. The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Aliment. 
Pharmacol. Ther. 1996;10 (suppl. 1), 39-50. 
Morgan DR, Dominguez RL, Keku TO, Heidt PE, Martin CF, Galanko JA, Omofoye OA, 
Sandler RS. Gastric cancer and the high combination prevalence of host cytokine 
genotypes and Helicobacter pylori in Honduras. Clin Gastroenterol Hepatol. 
2006;4(9):1103-11. 
Muñoz L, Camorlinga M, Hernández R, Giono S, Ramón G, Muñoz O, Torres J. Immune and 
proliferative cellular responses to Helicobacter pylori infection in the gastric mucosa 
of Mexican children. Helicobacter. 2007;12(3):224-30. 
Murakami K, Kodama M, Sato R, Okimoto T, Watanabe K, Fujioka T. Helicobacter pylori 
eradication and associated changes in the gastric mucosa. Expert Rev Anti Infect 
Ther 2005; 3(5): 757-64. 
Nilsson C, Skoglund A, Moran AP, Annuk H, Engstrand L, Normark S. An enzymatic ruler 
modulates Lewis antigen glycosylation of Helicobacter pylori LPS during persistent 
infection. Proc Natl Acad Sci USA. 2006;103(8):2863-8.  
Obonyo M, Sabet M, Cole SP, Ebmeyer J, Uematsu S, Akira S, Guiney DG. Deficiencies of 
myeloid differentiation factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce 
specific defects in macrophage cytokine secretion induced by Helicobacter pylori. 
Infect Immun. 2007;75(5):2408-14. 
Odenbreit S. Adherence properties of Helicobacter pylori: impact on pathogenesis and 
adaptation to the host. Int J Med Microbiol. 2005;295(5):317-24 
Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara 
S, Shimosegawa T. The polymorphism interleukin 8 -251 A/T influences the 
susceptibility of Helicobacter pylori related gastric diseases in the Japanese 
population. Gut. 2005;54(3):330-5. 
Oliveira AG, Santos A, Guerra JB, Rocha GA, Rocha AM, Oliveira CA, Cabral MM, 
Nogueira AM, Queiroz DM. babA2- and cagA-positive Helicobacter pylori strains are 
www.intechopen.com
 
A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
289 
associated with duodenal ulcer and gastric carcinoma in Brazil. J Clin Microbiol. 
2003;41(8):3964-6. 
Oliveira MJ, Costa AC, Costa AM, Henriques L, Suriano G, Atherton JC, Machado JC, 
Carneiro F, Seruca R, Mareel M, Leroy A, Figueiredo C. Helicobacter pylori induces 
gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent 
manner. J Biol Chem. 2006;281(46):34888-96. 
Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, Gemma S, Zanna I, D'Errico M, Zini E, 
Guidotti S, Valeri A, Fabbrucci P, Moretti R, Testai E, del Giudice G, Ottini L, 
Matullo G, Dogliotti E, Gomez-Miguel MJ. Interleukin-1 gene polymorphisms and 
gastric cancer risk in a high-risk Italian population. Am J Gastroenterol. 
2005;100(9):1941-8. 
Park ES, Do IG, Park CK, Kang WK, Noh JH, Sohn TS, Kim S, Kim MJ, Kim KM. 
Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients 
receiving adjuvant chemotherapy and is not associated with EBV infection. Clin 
Cancer Res. 2009;15(1):291-8. 
Partida-Rodríguez O, Torres J, Flores-Luna L, Camorlinga M, Nieves-Ramírez M, Lazcano E, 
Perez-Rodríguez M. Polymorphisms in TNF and HSP-70 show a significant 
association with gastric cancer and duodenal ulcer. Int J Cancer. 2010;126(8):1861-8. 
Peek RM Jr. Pathogenesis of Helicobacter pylori infection. Springer Semin Immun. 2005; 
27:197-215. 
Persson C, Engstrand L, Nyrén O, Hansson LE, Enroth H, Ekström AM, Ye W. Interleukin 1-
beta gene polymorphisms and risk of gastric cancer in Sweden. Scand J 
Gastroenterol. 2009;44(3):339-45. 
Przyklenk B, Bauernfeind A, Bornschein W, Emminger G, Heilmann K, Schweighart S. The 
role of Campylobacter (Helicobacter) pylori in disorders of the gastrointestinal 
tract. Infection. 1990;18(1):3-7. 
Quiros RM, Bui CL. Multidisciplinary approach to esophageal and gastric cancer, Surg. Clin. 
North Am. 2009;89(1): 79-96 , viii. 
Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C. Cytokine 
gene polymorphisms influence mucosal cytokine expression, gastric inflammation, 
and host specific colonisation during Helicobacter pylori infection. Gut. 
2004;53(8):1082-9 
Rautelin HI, Oksanen AM, Karttunen RA, Seppälä KM, Virtamo JR, Aromaa AJ, Kosunen 
TU. Association of CagA-positive infection with Helicobacter pylori antibodies of IgA 
class. Ann Med. 2000;32(9):652-6. 
Rieder G, Hofmann JA, Hatz RA, Stolte M, Enders GA. Up-regulation of inducible nitric 
oxide synthase in Helicobacter pylori-associated gastritis may represent an increased 
risk factor to develop gastric carcinoma of the intestinal type. Int J Med Microbiol. 
2003;293(6):403-12. 
Rossi G, Romagnoli S, Lauretti L, Pancotto L, Taccini E, Rappuoli R, Del Giudice G, 
Ruggiero P. Helicobacter pylori infection negatively influences pregnancy outcome in 
a mouse model. Helicobacter. 2004;9(2):152-7. 
Rudi J, Kolb C, Maiwald M, Zuna I, von Herbay A, Galle PR, Stremmel W. Serum antibodies 
against Helicobacter pylori proteins VacA and CagA are associated with increased 
risk for gastric adenocarcinoma. Dig Dis Sci 1997; 42(8):1652-9. 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
290 
Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, Canestrari E, Catalano 
V, Humar B, Ficarelli R, Bearzi I, Cascinu S, Naldi N, Testa E, Magnani M. 
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) 
polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and 
diffuse histotype. Ann Oncol. 2005;16(6):887-92. 
Sakuma K, Uozaki H, Chong JM, Hironaka M, Sudo M, Ushiku T, Nagai H, Fukayama M. 
Cancer risk to the gastric corpus in Japanese, its correlation with interleukin-1beta 
gene polymorphism (+3953*T) and Epstein-Barr virus infection. Int J Cancer. 
2005;115(1):93-7. 
Sánchez-Zauco NA, Giono-Cerezo S, Maldonado-Bernal C. [Toll-like receptors, pathogenesis 
and immune response to Helicobacter pylori]. Salud Publica Mex. 2010;52(5):447-54.  
Saxena A, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, Husain N. Polymorphism of -
765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease 
in addition to H pylori infection: a study from northern India. World J 
Gastroenterol. 2008;14(10):1498-503. 
Segal I, Ally R, Mitchell H. Helicobacter pylori--an African perspective. QJM. 2001;94(10):561-
5. 
Selbach M, Moese S, Hauck CR, Meyer TF, Backert S. Src is the kinase of Helicobacter pylori 
CagA protein in vitro and in vivo. J Biol Chem 2002; 277(9): 6775-8. 
Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, Sugano K, Kawano S, Chiba 
T. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations 
associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 
polymorphisms of 11 cytokine genes. J Gastroenterol Hepatol. 2007;22(5):729-37. 
Seo JH, Kim KH, Kim H. Role of proteinase-activated receptor-2 on cyclooxygenase-2 
expression in H. pylori-infected gastric epithelial cells. Ann N Y Acad Sci. 
2007;1096:29-36. 
Sheu SM, Sheu BS, Yang HB, Li C, Chu TC, Wu JJ. Presence of iceA1 but not cagA, cagC, 
cagE, cagF, cagN, cagT, or orf13 genes of Helicobacter pylori is associated with more 
severe gastric inflammation in Taiwanese. J Formos Med Assoc. 2002;101(1):18-23. 
Shin WG, Jang JS, Kim HS, Kim SJ, Kim KH, Jang MK, Lee JH, Kim HJ, Kim HY. 
Polymorphisms of interleukin-1 and interleukin-2 genes in patients with gastric 
cancer in Korea. J Gastroenterol Hepatol. 2008;23(10):1567-73. 
Shiotani A, Iishi H, Kumamoto M, Nakae Y. Helicobacter pylori infection and increased nitrite 
synthesis in the stomach. Inflammation and atrophy connections. Dig Liver Dis. 
2004;36(5):327-32. 
Shirai K, Ohmiya N, Taguchi A, Mabuchi N, Yatsuya H, Itoh A, Hirooka Y, Niwa Y, Mori N, 
Goto H. Interleukin-8 gene polymorphism associated with susceptibility to non-
cardia gastric carcinoma with microsatellite instability. J Gastroenterol Hepatol. 
2006;21(7):1129-35. 
Sicinschi LA, Lopez-Carrillo L, Camargo MC, Correa P, Sierra RA, Henry RR, Chen J, 
Zabaleta J, Piazuelo MB, Schneider BG. Gastric cancer risk in a Mexican population: 
role of Helicobacter pylori CagA positive infection and polymorphisms in 
interleukin-1 and -10 genes. Int J Cancer. 2006;118(3):649-57. 
Snider JL, Cardelli JA. Helicobacter pylori induces cancer cell motility independent of the c-
Met receptor. J Carcinog. 2009;8:7 
www.intechopen.com
 
A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
291 
Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfertheiner P. Anti-CagA and 
anti-VacA antibodies in Helicobacter pylori-infected patients with and without peptic 
ulcer disease in Serbia and Montenegro. Scand J Gastroenterol 2004; 39(3): 222-6. 
Son HJ, Rhee JC, Park DI, Kim YH, Rhee PL, Koh KC, Paik SW, Choi KW, Kim JJ. Inducible 
nitric oxide synthase expression in gastroduodenal diseases infected with 
Helicobacter pylori. Helicobacter. 2001;6(1):37-43. 
Starzyńska T, Ferenc K, Wex T, Kähne T, Lubiński J, Lawniczak M, Marlicz K, Malfertheiner 
P. The association between the interleukin-1 polymorphisms and gastric cancer risk 
depends on the family history of gastric carcinoma in the study population. Am J 
Gastroenterol. 2006;101(2):248-54. 
Stingl K, Uhlemann EM, Schmid R, Altendorf K, Bakker EP. Energetics of Helicobacter pylori 
and its implications for the mechanism of urease-dependent acid tolerance at pH 1. 
J Bacteriol. 2002;184(11):3053-60. 
Sugimoto M, Furuta T, Shirai N, Nakamura A, Xiao F, Kajimura M, Sugimura H, Hishida A. 
Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 
beta on development of peptic ulcer and gastric cancer. J Gastroenterol Hepatol. 
2007;22(1):51-9. 
Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, Hishida A. Effects 
of interleukin-10 gene polymorphism on the development of gastric cancer and 
peptic ulcer in Japanese subjects. J Gastroenterol Hepatol. 2007;22(9):1443-9. 
Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on 
development of gastric cancer and peptic ulcer. World J Gastroenterol. 
2010;16(10):1188-200. 
Suzuki M, Mimuro H, Kiga K, Fukumatsu M, Ishijima N, Morikawa H, Nagai S, Koyasu S, 
Gilman RH, Kersulyte D, Berg DE, Sasakawa C. Helicobacter pylori CagA 
phosphorylation-independent function in epithelial proliferation and 
inflammation. Cell Host Microbe. 2009;5(1):23-34. 
Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. 
Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and 
gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2487-
93. 
Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, Okubo M, Zaitsu Y, Ariyoshi K, 
Nakamura Y, Nawata R, Oka Y, Shirai M, Tanizawa Y. Molecular mimicry by 
Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-
associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004; 
124(1): 91-6. 
Takehara H, Iwamoto J, Mizokami Y, Takahashi K, Ootubo T, Miura S, Narasaka T, 
Takeyama H, Omata T, Shimokobe K, Ito M, Matsuoka T. Involvement of 
cyclooxygenase-2--prostaglandin E2 pathway in interleukin-8 production in gastric 
cancer cells. Dig Dis Sci. 2006;51(12):2188-97. 
Tanaka A, Kamada T, Yokota K, Shiotani A, Hata J, Oguma K, Haruma K. Helicobacter pylori 
heat shock protein 60 antibodies are associated with gastric cancer. Pathol Res 
Pract. 2009;205(10):690-4. 
Tatemichi M, Ogura T, Nagata H, Esumi H. Enhanced expression of inducible nitric oxide 




Gastric Carcinoma - Molecular Aspects and Current Advances 
 
292 
Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H. Increased risk of intestinal 
type of gastric adenocarcinoma in Japanese women associated with long forms of 
CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. 
Cancer Lett. 2005;217(2):197-202. 
Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV. Helicobacter pylori 
lipopolysaccharide promotes a Th1 type immune response in immunized mice. 
Vaccine. 2006;24(23):4987-94.  
Tiwari SK, Manoj G, Sharma V, Sivaram G, Saikant R, Bardia A, Sharma VK, Abid Z, Khan 
AA, Habeeb MA, Habibullah CM, Kumar BS, Nandan A. Relevance of Helicobacter 
pylori genotypes in gastric pathology and its association with plasma 
malondialdehyde and nitric oxide levels. Inflammopharmacology. 2010;18(2):59-64. 
Toller IM, Hitzler I, Sayi A, Mueller A. Prostaglandin E2 prevents Helicobacter-induced 
gastric preneoplasia and facilitates persistent infection in a mouse model. 
Gastroenterology. 2010;138(4):1455-67, 1467.e1-4. 
Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, 
Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, 
Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney 
K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback 
TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey 
L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. 
The complete genome sequence of the gastric pathogen Helicobacter pylori. 
Nature.1997;388(6642):539-47. 
Torres MM, Acosta CP, Sicard DM, et al. [Genetic susceptibility and risk of gastric cancer in 
a human population of Cauca, Colombia] Biomedica. 2004;24(2):153-62. 
Tsai HF & Hsu PN. Interplay between Helicobacter pylori and immune cells in immune 
pathogenesis of gastric inflammation and mucosal pathology. Cell Mol Immunol. 
2010;7(4):255-9. 
Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, Yasumaru M, Ishii S, Sasayama Y, 
Kawano S, Hayashi N. Helicobacter pylori eradication to prevent gastric cancer: 
underlying molecular and cellular mechanisms. World J Gastroenterol. 
2006;12(11):1671-80. 
Turbett GR, Høj PB, Horne R, Mee BJ. Purification and characterization of the urease 
enzymes of Helicobacter species from humans and animals. Infect Immun. 
1992;60(12):5259-66. 
Umehara S, Higashi H, Ohnishi N, Asaka M, Hatakeyama M. Effects of Helicobacter pylori 
CagA protein on the growth and survival of B lymphocytes, the origin of MALT 
lymphoma. Oncogene. 2003;22(51):8337-42. 
van den Engel NK, Winter H, Rüttinger D, Shau I, Schiller M, Mayer B, Moudgil T, 
Meimarakis G, Stolte M, Jauch KW, Fox BA, Hatz RA. Characterization of immune 
responses in gastric cancer patients: a possible impact of H. pylori to polarize a 
tumor-specific type 1 response? Clin Immunol. 2006;120(3):285-96. 
Varro A, Noble PJ, Pritchard DM, Kennedy S, Hart CA, Dimaline R, Dockray GJ. Helicobacter 
pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through 




A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
293 
Vaucher C, Janvier B, Nousbaum JB, Grignon B, Pezennec L, Robaszkiewicz M, Gouerou H, 
Picard B, Fauchere JL. Antibody response of patients with Helicobacter pylori-related 
gastric adenocarcinoma: significance of anti-cagA antibodies. Clin Diagn Lab 
Immunol 2000; 7(3): 463-7. 
Vieth M, Stolte M. Elevated risk for gastric adenocarcinoma can be predicted from 
histomorphology. World J Gastroenterol. 2006;12(38):6109-14. 
Vivas JR, Regnault B, Michel V, Bussière FI, Avé P, Huerre M, Labigne A, D' Elios MM, 
Touati E. Interferon gamma-signature transcript profiling and IL-23 upregulation 
in response to Helicobacter pylori infection. Int J Immunopathol Pharmacol. 
2008;21(3):515-26. 
Vorobjova T, Ren Z, Dunkley M, Clancy R, Maaroos HI, Labotkin R, Kull K, Uibo R. 
Response of IgG1 and IgG2 subclasses to Helicobacter pylori in subjects with chronic 
inflammation of the gastric mucosa, atrophy and gastric cancer in a country with 
high Helicobacter pylori infection prevalence. APMIS. 2006;114(5):372-80. 
Walduck AK, Weber M, Wunder C, Juettner S, Stolte M, Vieth M, Wiedenmann B, Meyer TF, 
Naumann M, Hoecker M. Identification of novel cyclooxygenase-2-dependent 
genes in Helicobacter pylori infection in vivo. Mol Cancer. 2009;8:22. 
Wang SK, Zhu HF, He BS, Zhang ZY, Chen ZT, Wang ZZ, Wu GL. CagA+ H pylori infection 
is associated with polarization of T helper cell immune responses in gastric 
carcinogenesis. World J Gastroenterol. 2007;13(21):2923-31. 
Wex T, Leodolter A, Bornschein J, Kuester D, Kähne T, Kropf S, Albrecht C, Naumann M, 
Roessner A, Malfertheiner P. Interleukin 1 beta (IL1B) gene polymorphisms are not 
associated with gastric carcinogenesis in Germany. Anticancer Res. 2010;30(2):505-
11. 
Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, 
Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. 
Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of 
China: A Randomized Controlled Trial. JAMA. 2004;291(2):187-194 
Wu MS, Lin JT, Hsu PN, Lin CY, Hsieh YT, Chiu YH, Hsueh PR, Liao KW. Preferential 
induction of transforming growth factor-beta production in gastric epithelial cells 
and monocytes by Helicobacter pylori soluble proteins. J Infect Dis. 2007;196(9):1386-
93. 
Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with 
the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer. 2003;104(5):617-23. 
Wu YY, Tsai HF, Lin WC, Hsu PI, Shun CT, Wu MS, Hsu PN. Upregulation of CCL20 and 
recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter pylori gastritis. 
Infect Immun. 2007;75(9):4357-63.  
Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: 
implications in gastric carcinogenesis. Am J Gastroenterol. 2001;96(1):16-26. 
Xiao H, Jiang Y, Li R, Xia B. [Association of IL-10 gene polymorphisms with gastroduodenal 
diseases in Hubei Han population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 
2009;26(4):423-6. 
Xue LJ, Su QS, Yang JH, Lin Y. Autoimmune responses induced by Helicobacter pylori 
improve the prognosis of gastric carcinoma. Med Hypotheses. 2008;70(2):273-6.  
Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between 
cytokines and Helicobacter pylori in gastric cancer. Helicobacter. 2001;6(2):116-24. 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
294 
Yang J, Hu Z, Xu Y, Shen J, Niu J, Hu X, Guo J, Wei Q, Wang X, Shen H. Interleukin-1B gene 
promoter variants are associated with an increased risk of gastric cancer in a 
Chinese population. Cancer Lett. 2004;215(2):191-8.  
Yang JJ, Ko KP, Cho LY, Shin A, Gwack J, Chang SH, Shin HR, Yoo KY, Kang D, Park SK. 
The role of TNF genetic variants and the interaction with cigarette smoking for 
gastric cancer risk: a nested case-control study. BMC Cancer. 2009;9:238. 
Yoo EJ, Park SY, Cho NY, Kim N, Lee HS, Kim D, Kang GH. Influence of IL1B 
polymorphism on CpG island hypermethylation in Helicobacter pylori-infected 
gastric cancer. Virchows Arch. 2010;456(6):647-52. 
Zabaleta J, Camargo MC, Ritchie MD, Piazuelo MB, Sierra RA, Turner SD, Delgado A, 
Fontham ET, Schneider BG, Correa P, Ochoa AC. Association of haplotypes of 
inflammation-related genes with gastric preneoplastic lesions in African Americans 
and Caucasians. Int J Cancer. 2011;128(3):668-75. 
Zabaleta J, McGee DJ, Zea AH, Hernández CP, Rodriguez PC, Sierra RA, Correa P, Ochoa 
AC. Helicobacter pylori arginase inhibits T cell proliferation and reduces the 
expression of the TCR zeta-chain (CD3zeta). J Immunol. 2004;173(1):586-93. 
Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, Greco E, Gallo N, Rugge M, 
Di Mario F, Plebani M. Pro- and anti-inflammatory cytokines gene polymorphisms 
and Helicobacter pylori infection: interactions influence outcome. Cytokine. 
2005;29(4):141-52. 
Zhang LJ, Wang SY, Huo XH, Zhu ZL, Chu JK, Ma JC, Cui DS, Gu P, Zhao ZR, Wang MW, 
Yu J. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric 
precancerous lesions. World J Gastroenterol. 2009;15(22):2731-8. 
Zhang XM, Miao XP, Tan W, Sun T, Guo YL, Zhao D, Lin DX. [Genetic polymorphisms in 
the promoter region of cyclooxygenase-2 and their association with risk of gastric 
cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006;28(2):119-23. 
Zhu F, Loh M, Hill J, Lee S, Koh KX, Lai KW, Salto-Tellez M, Iacopetta B, Yeoh KG, Soong R; 
Singapore Gastric Cancer Consortium. Genetic factors associated with intestinal 
metaplasia in a high risk Singapore-Chinese population: a cohort study. BMC 
Gastroenterol. 2009;9:76. 
Zhu KX, Li YM, Li X, Zhou WC, Shan Y, Liu T. Study on the association of COX-2 genetic 
polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu 
province in China. Mol Biol Rep. 2011;38(1):649-55. 
Zhuang X, Lin S, Zheng J, Wang L, Sun G, Li Y. The prognostic research of expression and 
relationship between Helicobacter pylori of c-met oncogene correlation with gastric 
mucosal proliferation. Zhonghua Nei Ke Za Zhi. 2001;40(6):381-4. 
www.intechopen.com
Gastric Carcinoma - Molecular Aspects and Current Advances
Edited by Prof. Mahmoud Lotfy
ISBN 978-953-307-412-2
Hard cover, 354 pages
Publisher InTech
Published online 15, June, 2011
Published in print edition June, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Gastric cancer is one of the most common tumors worldwide. It has a heterogeneous milieu, where the genetic
background, tumor immunology, oxidative stress, and microbial infections are key players in the multiple
stages of tumorigenesis. These diverse factors are linked to the prognosis of the gastric cancer and the
survival of gastric cancer patients. This book is appropriate for scientists and students in the field of oncology,
gastroenterology, molecular biology, immunology, cell biology, biology, biochemistry, and pathology. This
authoritative text carefully explains the fundamentals, providing a general overview of the principles followed
by more detailed explanations of these recent topics efficiently. The topics presented herein contain the most
recent knowledge in gastric cancer concerning the oncogenic signaling, genetic instability, the epigenetic
aspect, molecular features and their clinical implications, miRNAs, integrin and E-cadherin, carbohydrate-
associated-transferases, free radicals, immune cell responses, mucins, Helicobacter-pylori, neoadjuvant and
adjuvant therapy, prophylactic strategy for peritoneal recurrence, and hepatic metastasis.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Li-Jun Xue, Quan-Sheng Su, Xiao-Bei Mao, Xiao-Bei Liu, Qing Lin, Chang Liu, Yong Lin, Ji-Hong Yang, Hong-
Ju Yu and Xiao-Yuan Chu (2011). A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma,
Gastric Carcinoma - Molecular Aspects and Current Advances, Prof. Mahmoud Lotfy (Ed.), ISBN: 978-953-
307-412-2, InTech, Available from: http://www.intechopen.com/books/gastric-carcinoma-molecular-aspects-
and-current-advances/a-double-edged-sword-roles-of-helicobacter-pylori-in-gastric-carcinoma
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
